



# Medical Coverage Policy

Effective Date.....10/15/2022  
Next Review Date.....10/15/2023  
Coverage Policy Number ..... 0404

## Sacral Nerve and Tibial Nerve Stimulation for Urinary Voiding Dysfunction, Fecal Incontinence and Constipation

### Table of Contents

Overview .....	1
Coverage Policy.....	1
General Background.....	3
Medicare Coverage Determinations .....	20
Coding Information .....	20
References .....	22

### Related Coverage Resources

- [Biofeedback](#)
- [Electrical Stimulation Therapy and Devices](#)
- [Fecal Bacteriotherapy](#)

#### INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Each coverage request should be reviewed on its own merits. Medical directors are expected to exercise clinical judgment and have discretion in making individual coverage determinations. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

### Overview

This Coverage Policy addresses sacral nerve stimulation (SNS), percutaneous tibial nerve stimulation (PTNS) and implantable tibial nerve stimulation as a treatment for the involuntary leakage of urine or stool and constipation.

### Coverage Policy

#### Sacral Nerve Stimulation (SNS)

##### Urinary Voiding Dysfunction

A screening trial of sacral nerve stimulation (SNS) with an external stimulator for either percutaneous nerve evaluation (PNE) or an implanted lead is considered medically necessary for the treatment of any

**of the following urinary voiding dysfunctions when there is failure, intolerance or contraindication to conservative medical management:**

- urinary urge incontinence
- nonobstructive urinary retention
- overactive bladder (OAB) symptoms, including urinary frequency and/or urgency, with or without incontinence

**Permanent SNS implantation for the treatment of urinary voiding dysfunction is considered medically necessary when there has been a beneficial clinical response to a screening trial of SNS as evidenced by at least a 50% improvement in reported symptoms.**

## **Fecal Incontinence**

**A screening trial of sacral nerve stimulation (SNS) with an external stimulator for either percutaneous nerve evaluation (PNE) or an implanted lead is considered medically necessary for the treatment of fecal incontinence when ALL of the following criteria are met:**

- failure, intolerance, or contraindication to conservative medical management
- absence of a significant anorectal malformation or chronic inflammatory bowel disease involving the anus
- fecal incontinence is not secondary to another neurological condition such as peripheral neuropathy or complete spinal cord injury

**Permanent SNS implantation for fecal incontinence is considered medically necessary when there has been a beneficial clinical response to a screening trial of SNS as evidenced by at least a 50% improvement in reported symptoms.**

**The replacement/revision of a sacral nerve stimulator generator/battery and/or lead/electrode and/or patient programmer is considered medically necessary for an individual who meets ALL of the above criteria and the existing generator/lead/programmer is no longer under warranty and cannot be repaired.**

**SNS for the treatment of any other indication, including constipation is considered experimental, investigational or unproven.**

## **Percutaneous Tibial Nerve Stimulation (PTNS)**

### **Overactive Bladder**

**A standard treatment regimen of 30-minute weekly sessions for 12 weeks of percutaneous tibial nerve stimulation (PTNS) is considered medically necessary for the treatment of overactive bladder (OAB) symptoms when there is failure, intolerance, or contraindication to conservative medical management (e.g., bladder training, pharmacotherapy).**

**Maintenance therapy of 30-minute monthly sessions of percutaneous tibial nerve stimulation (PTNS) is considered medically necessary for the treatment of overactive bladder (OAB) symptoms when there is a beneficial clinical response to the initial 12-week treatment course as evidenced by at least a 50% improvement in reported symptoms.**

**More than 12 PTNS treatments is considered not medically necessary when there is no improvement of OAB symptoms as documented by a voiding diary and/or with urodynamic testing.**

**PTNS for any other urinary indication is considered experimental, investigational or unproven.**

### **Fecal Incontinence and Constipation**

**Percutaneous posterior tibial nerve stimulation (PTNS) for fecal incontinence and constipation is considered experimental, investigational or unproven.**

## **Implantable Tibial Nerve Stimulation**

**Implantable tibial nerve stimulation for the treatment of urinary voiding dysfunction (e.g., overactive bladder, urinary urge incontinence), fecal incontinence and constipation is considered experimental, investigational or unproven.**

## **General Background**

### **Sacral Nerve Stimulation (SNS)**

Sacral nerve stimulation (SNS), also known as sacral nerve neuromodulation, involves the implantation of a permanent device that modulates the neural pathways. The exact mechanism of action is unclear (Abello and Das, 2018). Sacral nerve stimulation (SNS) applies a low amplitude electrical current to a sacral nerve through an electrode that is placed through a corresponding sacral foramen. The stimulation of the sacral nerves leads to recruitment of the pelvic floor musculature and pelvic organs, leading to improvement in pelvic floor function. The third sacral foramen is the level at which an optimal response is most commonly elicited. The third sacral nerve root contains afferent sensory and efferent autonomic motor nerves and voluntary somatic fibers, which may, alone or in harmony, create the beneficial effect elicited by SNS (Mellgren, 2010).

Syan et al. (2020) conducted study that analyzed if racial and socioeconomic factors influenced the utilization of advanced therapies in commercially insured OAB Patients. Through a query of Optum, a national claims database, they found that Asians and Hispanics were least likely to utilize SNS therapy and most likely to use PTNS compared to Blacks and Whites. Female gender, younger age (< 65), higher annual income  $\geq$  \$40K and prior use of oral medications were significantly associated with receiving advanced therapies. In addition, non-white race, lower education level (less than a bachelor's degree) and Northeast region were associated with a lower likelihood of receiving advanced therapies ( $p < 0.05$  for all).

Prior to the implantation of a permanent SNS system, patients are screened for potential therapeutic benefit by undergoing a screening trial period. There are two methods that can be used for screening prior to permanent implantation, a percutaneous nerve evaluation (PNE) or a two staged implantation approach. During a PNE, a non-anchored test lead is placed percutaneously at the sacral nerve site using a lead introducer, and then a percutaneous lead extension is connected to an external test stimulator. The external test stimulator device provides continuous stimulation. Following an adequate test period for efficacy or lack, thereof (efficacy defined as a  $\geq 50\%$  subjective and/or objective response), the electrode is removed. If the screening trial is successful, a permanent lead and implantable pulse generator (IPG) may be placed in the operating room (Hassouna and Alabbad, 2018; Abello and Das, 2018).

The two staged implantation method is indicated for patients who fail PNE, for patients with an inconclusive PNE, for patients who had a successful PNE to refine patient selection further or instead of PNE. During the first stage, a permanent quadripolar tined lead is implanted, connected subcutaneously to a temporary extension lead and then connected to an external pulse generator. If the trial is successful, a second-stage procedure is done for placement of the permanent IPG. The trial period can vary between three days and up to two weeks. Shorter trials are typically done with PNE (3–5 days), while the longer trial periods up to two weeks can be done with the tined lead as it has a lower risk of lead migration. Complications to SNS include device-related pain, need for revision, infection, and neurologic complications (Hassouna and Alabbad, 2018; Abello and Das, 2018).

SNS has been proposed for the treatment of urinary voiding dysfunction, including intractable urinary urge incontinence, nonobstructive urinary retention, urinary urgency/frequency, fecal incontinence, and several other indications.

### **Urinary Voiding Dysfunction**

Urinary voiding dysfunction is usually defined as the inability to control urination. Urinary voiding disorders are generally divided into five types, depending on the pathophysiology involved: urge incontinence—a subtype is urgency-frequency syndrome, overflow incontinence, stress incontinence, mixed incontinence, functional incontinence.

Treatment options for urinary voiding disorders may include behavioral strategies, pharmacological interventions, temporary electrical stimulation, or reconstructive surgery. Less invasive modalities are generally used initially before irreversible, reconstructive surgery is considered.

Sacral nerve stimulation (SNS) may be indicated in patients who demonstrate at least 50% urinary incontinence symptom relief during test stimulation and who have failed or not tolerated more conservative treatments (e.g., behavioral strategies, pharmacological interventions). The criteria for a positive response vary slightly; however, at least a 50% improvement in one or more primary symptoms is considered the standard for a clinically significant response (Schmidt, 1999). It is not proposed for the treatment of stress incontinence, the most common type of urinary dysfunction (Hassouna, 2000).

The precise mode of action of neuromodulation on the lower urinary tract is unclear. When a nerve is stimulated, signals travel both toward the periphery and toward the central nervous system (Herbison, 2009). According to the manufacturer of the InterStim® System for Urinary Control (Medtronic, Inc., Minneapolis, MN), SNS is not intended for patients with mechanical obstruction such as benign prostatic hypertrophy, cancer, or urethral stricture. Medtronic also states that the safety and effectiveness of SNS has not been established for bilateral stimulation, patients with neurological disease origins (e.g., multiple sclerosis), pregnancy and delivery or for children under the age of 16 (Medtronic, Inc., 2019).

Sacral nerve stimulation is considered an appropriate treatment option for individuals with refractory voiding dysfunction, with failure of, or contradiction or intolerance to conservative medical management after a 50% improvement is noted in response to a screening trial.

**U.S. Food and Drug Administration (FDA):** In 1997, the InterStim® Therapy System for Urinary Control (Medtronic, Inc., Minneapolis, MN) received premarket approval from the FDA “for the treatment of urinary urge incontinence in patients who have failed or could not tolerate more conservative treatments”. In 1999, a supplement expanded the indication to include “urinary retention, and significant symptoms of urgency/frequency”. In August 2001, the FDA approved the Model 3550-03 Twist-Lock Screening Cable and Model 3550-05 Percutaneous Extension and Tunneling Tool Kit for temporary SNS as part of a staged implant screening technique for patients who had inconclusive results following standard percutaneous testing. A supplement in 2002, granted approval for the revised indication: “InterStim Therapy for Urinary Control is indicated for the treatment of urinary retention and the symptoms of overactive bladder, including urinary urge incontinence and significant symptoms of urgency-frequency alone or in combination, in patients who have failed or could not tolerate more conservative treatments”. A supplement in 2020 (P970004/S302), granted approval for the InterStim Micro System with full-body MR conditional labeling, which is an updated version of the InterStim II System. The modifications include new SureScan MRI leads, an updated Verify Evaluation System that can accommodate newly developed leads, and related labeling updates (FDA, 2020). A supplement in 2022 (P970004/S340), granted approval for the InterStim X INS that features more than 10 years of battery life without the need to recharge, with low energy settings, the device can last up to 15 years (FDA, 2022; Medtronic, 2022).

In 2019, the Axonics Sacral Neuromodulation System (Axonics Modulation Technologies, Inc., Irvine, California) received premarket approval from the FDA “for the treatment of urinary retention and the symptoms of overactive bladder, including urinary urge incontinence and significant symptoms of urgency-frequency alone or in combination, in patients who have failed or could not tolerate more conservative treatments” (FDA, 2019a).

**Literature Review - Sacral Nerve Stimulation (SNS) for Urinary Voiding Dysfunction:** Several randomized clinical trials (RCTs), prospective case series, retrospective analyses and systematic reviews have demonstrated > 50% improvement in incontinence symptoms, decrease in the number of daily catheterizations required, an increase in the volume of urine obtained per void, and a decrease in post-void residual urine volume with the use of sacral nerve stimulation (SNS) (Szymański, et al., 2019; Tutolo, et al., 2018; Noblett, et al., 2014; Herbison,

2009; White, 2008; van Kerrebroeck, 2007, Sutherland, 2007). Adverse events reported include changes in stimulation sensation, loss of efficacy, pain at the implantation site, and the need for intravenous antibiotics.

Siegel, et al. (2015) published their results of a post-approval RCT (n=147) comparing SNS (n=70) to standard medical therapy (n=77) for OAB. Inclusion criteria were failed or not a candidate for conservative treatment, including pharmacotherapy. Exclusion criteria included severe or uncontrolled diabetes, neurological diseases such as multiple sclerosis, clinically significant peripheral neuropathy or complete spinal cord injury (e.g., paraplegia), symptomatic urinary tract infection, and primary stress incontinence. All subjects were required to discontinue OAB medications for four days prior to their initial voiding diary. The primary outcome measure of OAB therapeutic success defined as 50% improvement in average leaks/day or voids/day from baseline or a return to normal voiding frequency (< 8 voids/day). Secondary outcomes included quality of life measures. A total of 59 patients from the SNS group and 71 patients from the standard medical therapy group (anticholinergic or antimuscarinic medication) completed six month follow-up. For the primary outcome, 61% of SNS subjects demonstrated therapeutic success at six months versus 42% of the standard medical therapy subjects (p<0.02). The SNS group also showed greater improvement in all domains of the quality of life scales compared to the standard medical therapy group (p<0.001). Adverse events related to the SNS device occurred in 30.5% (18/59) of subjects with a lead implant. OAB medication-related events occurred in 27.3% (21/77) of standard medical therapy subjects. Acknowledged study limitations include the homogeneous nature of the population and the lack of blinding. Study results suggested that SNS results in a greater reduction of OAB symptoms and improvement in quality of life indicators than standard medical therapy.

A systematic review by Herbison et al. (2009), evaluated twelve reports of eight randomized studies of 500 adults with urge urinary incontinence, overactive bladder syndrome (i.e., urgency or frequency), and urinary retention. About 50% of patients in the stimulation group achieved complete continence or an improvement greater than 90% of the main incontinence symptoms. Eighty-seven percent of patients achieved a 50% improvement. In all reports, participants had failed conventional treatments before randomization. It is unclear whether the studies all used the same implant. The authors noted that several long-term studies had poor rates of follow-up. Thirty percent or more potentially eligible patients were not implanted and 30% or more of those implanted did not gain benefit. Overall continuous stimulation offered benefits for carefully selected individuals with overactive bladder syndrome and for those with urinary retention but no structural obstruction.

Van Kerrebroeck et al. (2007) reported long-term results of a five-year prospective multi-center study that evaluated the safety and efficacy of SNS in patients with refractory urge incontinence, urgency frequency, and retention. One hundred sixty-three patients enrolled in the study and after undergoing test stimulation 152 underwent SNS implantation. Implanted devices varied between patients. Three-day voiding diaries were collected annually for five years-diary variables differed according to the type of urinary disorder. Simple uroflow and quality of life questionnaires, such as the Short Form-36 and the Beck Depression Inventory were used. Detailed data were also collected on any concomitant treatment for the urological condition and on any therapy or patient related complications. Clinical success was defined as  $\geq 50\%$  improvement in baseline. For patients with urge incontinence mean leaking episodes per day decreased from 9.6 to 3.9 at five years. For patients with urgency frequency, mean voids per day decreased from 19.3 to 14.8 and mean volume voided per void increased from 92.3 ml to 165.2 ml. For patients with retention the mean volume per catheterization decreased from 379.9 ml to 109.2 ml, and the mean number of catheterizations decreased from 5.3 to 1.9. All changes were statistically significant (p<0.001). No life threatening or irreversible adverse events occurred; however, in 102 patients 279 device or therapy related adverse events were observed. At five years after implantation, 68% of patients with urge incontinence, 56% with urgency frequency and 71% with retention had successful outcomes.

There is sufficient high quality controlled clinical trial data to demonstrate the safety and effectiveness of sacral nerve stimulation for the treatment of individuals with refractory voiding dysfunction, with failure of, or contradiction or intolerance to conservative medical management after a 50% improvement is noted in response to a percutaneous screening trial.

## **Fecal Incontinence**

Fecal incontinence is the inability to control bowel movements leading to feces leaking from the rectum. The reported prevalence in the general population is 2% to 3%. Severe fecal incontinence can be socially isolating as an individual with the condition may alter his/her lifestyle to accommodate the likelihood of bowel leakage. Fecal

incontinence may be caused by several factors including muscle damage, such as that experienced after childbirth, or after rectal surgery, or from damage to the nerves that control the anal muscle or regulate rectal sensation (Wald, 2016). Additionally, it may be caused by a reduction in the elasticity of the rectum, which shortens the time between the sensation of the stool and the urgent need to have a bowel movement. Surgery or radiation injury can scar and stiffen the rectum. Inflammatory bowel disease can also make the rectum less elastic. Treatment depends on the cause of the incontinence and may include dietary changes, drug therapy, bowel training, or surgery. Surgical treatment options for fecal incontinence include an overlapping sphincter repair, total pelvic floor reconstruction or, less commonly, artificial bowel sphincters (Fargo & Latimer, 2012). Fecal incontinence remains a therapeutic problem in many patients when conservative measures, such as dietary advice, pelvic floor exercises and medical therapy with bulking agents, fails and sphincter repair is unsuccessful or inappropriate (Chan, 2008; Leroi, et al., 2005; Jarrett, et al., 2004). Sacral nerve stimulation (SNS) has been proposed for the treatment of fecal incontinence.

The exact mechanism of action of SNS for fecal incontinence remains unclear. According to Gladman (2008), "Although it was initially thought that SNS would directly augment anal sphincter function and improve fecal incontinence, the observation that improved continence occurs without change in anal sphincter function has led to the suggestion that SNS has predominantly suprasphincteric effects. The mechanism of action of SNS is not conclusively proved and may involve direct effects peripherally on colorectal sensory or motor function, or central effects at the level of spinal cord or brain." Further neurophysiological research is necessary to understand the mechanisms of sacral neuromodulation" (Melenhorst, et al., 2007).

Indications and patient selection for the use of sacral nerve stimulation (SNS) for the treatment of fecal incontinence continue to evolve. Initial study eligibility included patients with a functionally deficient but morphologically intact anal sphincter. More recently, inclusion criteria has been extended to include those with external and internal sphincter defects, secondary to cauda equina syndrome, scleroderma, rectal prolapse repair, low anterior resection of the rectum, and partial spinal injuries (Gladman, 2008; Jarrett, et al., 2004).

**U.S. Food and Drug Administration (FDA):** In March 2011, Medtronic, Inc. (Minneapolis, MN) received premarket approval from the FDA for the Medtronic InterStim® Sacral Nerve Stimulation Therapy System. This device is indicated for the treatment of chronic fecal incontinence in patients who have failed or are unable to tolerate more conservative treatments (FDA, 2011). A supplement in 2020 (P080025/S197), granted approval for the InterStim Micro System with full-body MR conditional labeling, which is an updated version of the InterStim II System. The modifications include new SureScan MRI leads, an updated Verify Evaluation System that can accommodate newly developed leads, and related labeling updates (FDA, 2020). A supplement in 2022 (P080025/235), granted approval for the InterStim X INS that features more than 10 years of battery life without the need to recharge, with low energy settings, the device can last up to 15 years (FDA, 2022; Medtronic 2022).

In 2019, the Axonics Sacral Neuromodulation System (Axonics Modulation Technologies, Inc., Irvine, California) received premarket approval from the FDA "for the treatment of chronic fecal incontinence in patients who have failed or are not candidates for more conservative treatments" (FDA, 2019b).

**Literature Review - Sacral Nerve Stimulation (SNS) for Fecal Incontinence:** Randomized controlled data is limited regarding the effects of SNS; however, there is sufficient evidence to support the use of SNS for the treatment of fecal incontinence following a successful screening trial. A number of prospective case series and retrospective reviews have noted improvements in the frequency of incontinence episodes and quality of life measures as self-reported in bowel diaries and quality of life scales (Rydningen, et al., 2017; Hull, et al., 2013; Damon, et al., 2013; Devroede, 2012; Boyle, et al., 2011; Mellgren, 2011; Uludag, et al., 2011; Michelson, et al., 2010; Wexner, et al., 2010; Matzel, et al., 2009; Meurette, et al., 2009; Chan, 2008).

A 2015 Hayes Medical Technology Directory report evaluated the evidence (n=15 studies) on the use of SNS in a staged approach for FI. The review included RCTs (n=2), randomized crossover trials (n=2 studies), nonrandomized comparative studies (n=3), and pretest/posttest studies (n=8) that examined SNS for the treatment of patient with severe refractory FI. Study sample sizes ranged from 16 to 272 subjects. Outcomes measured were QoL, disease severity, post-implantation surgical rates, and complication rates. Follow-up ranged from six months to five years. The overall quality of the body of evidence was found to be moderate despite the low quality of individual studies because the evidence regarding QoL and disease severity was

consistent and in favor of SNS. It was summarized that findings suggest that SNS may offer a highly effective treatment alternative for patients with severe FI for whom other treatments have failed. However, the procedure carries potential risks for complications. Studies identified in the 2019 update of the Hayes Medical Technology Directory report did not change this conclusion (Hayes, 2015).

In a prospective uncontrolled trial investigating the effectiveness of SNS for fecal incontinence, Wexner et al. (2010) evaluated 285 patients. One hundred thirty-three patients underwent peripheral nerve stimulation and 120 of those individuals received permanent SNS. Mean follow-up was 28 months. Study participants were requested to complete a five-question bowel diary at baseline, during test stimulation, and at three, six, and 12 months and annually after study closure. Quality of life and well-being were also assessed by additional questionnaires. At 12 months, 83% achieved therapeutic success defined as achieving  $\geq 50\%$  reduction in the number of incontinent episodes per week compared to the baseline; 85% achieved therapeutic success at 24 months. Forty percent of those receiving SNS achieved 100% improvement in incontinent episodes per week and incontinent days per week at 12 months. Incontinence episodes decreased from a mean of 9.4 per week at baseline to 1.9 at 12 months, and 2.9 at two years. Adverse event (AE) rates were high with 696 AEs reported. Three hundred seven AEs in 96 patients were related to the device or therapy. Twenty-six AEs were considered serious and included implant site pain, hematomas, lead fractures, lead migrations or dislodgments, extremity pain, skin irritation, paresthesia's, implant site infection, change in sensation of stimulation, urinary incontinence, and diarrhea. 10.8% of patients experienced implant site infection and 5.8% required surgical removal of the implant. Study limitations included an uncontrolled, nonrandomized design and short-term follow-up.

Mellgren et al. (2011) reported results of a three-year follow-up assessment of the trial by Wexner et al. Of 120 patients receiving chronic SNS, eighty-three patients completed part or all of the assessment, with 86% of patients reporting  $\geq 50\%$  reduction in the number of incontinent episodes per week compared with baseline. Perfect continence was reported by 40% of study participants. Improvements in the Fecal Incontinence Quality of Life scale were reported at 12, 24, and 36 months of follow-up. Device- or therapy-related adverse events included implant site pain (28%), paresthesia (15%), change in the sensation of stimulation (12%), and infection (10%). Limitations included an uncontrolled, nonrandomized study design.

Tan et al. (2011) performed a meta-analysis of thirty-four studies, including 944 patients undergoing peripheral nerve evaluation; 665 underwent permanent sacral nerve stimulation (SNS). Study design included twenty-eight prospective non-randomized trials; two retrospective trials, one prospective cross-sectional study, two double-blind cross-over trials, and a randomized controlled trial. Follow-up ranged from two weeks to 35 weeks. All studies reported on at least one outcome of interest. Studies were analyzed for functional outcomes (i.e., weekly incontinence episodes, Wexner (Cleveland) incontinence scores, and ability to defer defecation.), Quality of Life outcomes (i.e., SF-36 questionnaire), fecal incontinence quality of life (FIQL) questionnaire (the American Society of Colon and Rectal Surgery [ASCRS] quality of life questionnaire), anal manometry (i.e., resting and squeeze pressures), and rectal sensitivity (i.e., threshold, urge and maximum tolerable volumes). Regarding functional outcomes, twenty-eight studies reported on incontinence episodes per week; all studies reported a decrease following SNS, compared with conservative therapy ( $p < 0.001$ ). Sixteen studies reported at the time patients were able to defer defecation; seven of these were excluded from analysis as data were reported in groups. In the nine studies included in the analysis there was a significant increase in the ability to defer defecation following sacral nerve stimulation ([SNS],  $p < 0.001$ ). Regarding Quality of Life outcomes, there was an increase in the weighted mean difference of all SF-36 outcomes in favor of sacral nerve stimulation (SNS), with all but one (bodily pain,  $p = 0.13$ ) reaching significance. Overall, there was a significant increase in the SNS group in all subcategories of the FIQL questionnaire. In the studies included in the analysis for resting and squeeze pressure, both pressures were found to be significantly higher in the SNS group ( $p < 0.001$ ). Regarding rectal sensitivity, twenty-two studies reported on threshold, 21 on urge and 20 on maximum tolerable volumes. Outcomes were significant only for threshold volume ( $p = 0.03$ ). Decreases in urge volume and maximum tolerable volume did not reach statistical significance ( $p = 0.25$  and  $p = 0.48$ , respectively). The most common complications among the 665 patients that underwent permanent SNS implantation were pain or local discomfort (6%), lead displacement or breakage (4%), infection (3%) and sarcoma (3%). The authors noted that "the wide range of patients and consistently positive results in functional outcomes suggest that a placebo effect is unlikely; but further randomized controlled trials would be useful in confirming this." The authors also noted that SNS improves functional outcomes and quality of life in patients with fecal incontinence where conventional non-surgical therapies have failed.

Mowatt et al. (2008) performed a systematic review of three randomized studies involving a total of 38 patients. One study included 34 patients; each of the other studies included two patients. Thirty-one patients received sacral nerve stimulation (SNS). Two studies assessed the effects of SNS for fecal incontinence (n=36); one assessed the effects of SNS on constipation (n=2). All three studies had a double-blinded crossover design. According to the authors the very limited evidence suggests that for some selected patients, SNS can reduce episodes of fecal incontinence and urgency, and improve the ability to defer defecation, leading to a better quality of life. However, a minority may get worse despite apparently successful testing before permanent implantation.

Tjandra et al. (2008) published outcomes of the largest randomized controlled trial (RCT) to date involving 120 patients; 60 were randomized to the SNS group and 60 patients were randomized to best supportive therapy (i.e., pelvic floor exercises, bulking agents, dietary modifications, biofeedback). Fifty-four patients in the SNS group had  $\geq 50\%$  improvement in continence during the screening period with 53 patients undergoing SNS implantation. Follow-up was 12 months. Both groups were assessed at baseline, three, six, and 12 months.

The control group demonstrated no significant improvements in fecal continence as assessed by bowel diary, the Wexner score, and several quality of life scales. In the SNS group, mean incontinent episodes per week significantly improved at six and 12 months, as did mean incontinent days per week ( $p < 0.0001$  and  $0.0001$ , respectively). Urge and passive incontinence also improved. Ability to defer defecation improved significantly but the ability to completely empty the bowel was not affected. One hundred percent fecal competence was achieved in 47.2% of patients. According to the authors, improvement in quality of life was noted immediately after implantation of the SNS, with significant improvement in all domains ( $p < 0.0001$ ). None of the patients had worsening of fecal incontinence as a result of SNS. There were no statistically significant changes in the maximum resting and squeeze anal canal pressures in either group. Adverse events in the SNS group included seroma (2%), pain at the implant site (6%) and tingling in the vaginal area (9%). In the control group six patients complained of constipation due to Imodium use. The authors noted that the presence of a control group helps reject the concept of a placebo effect. Data suggested that SNS may result in a decrease in the number incontinent episodes per week.

The Agency for Healthcare Research and Quality (Shamliyan, et al., 2007) reported results of a systematic review of several studies examining the effects of electrical stimulation or neuromodulation (i.e., SNS) on fecal incontinence. AHRQ noted that individualized sacral nerve continuous stimulation improved incontinence in 89% of patients with severe baseline incontinence compared to 17 percent after sham stimulation. However, the treatments did not improve quality of life with random differences after active and sham stimulation. All randomized controlled trials (RCTs) reported small inconsistent differences in anal manometry outcomes after active stimulation compared to the control. According to AHRQ electrical stimulation did not improve fecal incontinence in the majority of RCTs. "The significant relative improvement after sacral nerve stimulation in patients with severe baseline incontinence requires future confirmation in a large well designed RCT with long-term follow-up.

Regarding the use of self-report questionnaires to assess fecal incontinence, AHRQ also noted "Few validated questionnaires and instrumental methods were examined to detect the presence and baseline of causes for fecal incontinence with no consensus on which test is the gold standard. Patient reports do not correlate well with anatomical and physiological measures and anal manometry does not correlate well with ultrasonography or sigmoidoscopy. The severity and impact of incontinence on quality of life can be estimated from self-reported frequency, amount of leakage, and restrictions on daily activities, but not from instrumental methods. However, treatment decisions were made based on objective measures of incontinence. Instrumental physiological measurements that are associated with patient outcomes and may reflect better effects of different interventions should be analyzed in well-designed experiments."

Leroi et al. (2005) reported outcomes from a randomized double-blind crossover study involving 34 patients with fecal incontinence. Patients initially underwent peripheral nerve evaluation testing and if  $\geq 50\%$  improvement in incontinence was demonstrated they progressed to sacral nerve stimulation (SNS) implantation. All thirty-four patients received SNS; 27 patients were randomized to the crossover period, and 24 completed the study.



Outcomes measured were frequency of fecal incontinence and urgency episodes, delay in postponing defecation, score severity, feeling of improvement, preference for ON or OFF mode of stimulation, quality of life, and manometric measurements. Follow-up was 12 months. There was a significant treatment effect with a decrease in the median frequency of FI episodes between the ON and OFF periods; however, median incontinence episodes decreased in both the ON and OFF periods (90% versus 76%, respectively), as did defecation postponement (89% versus 63%, respectively). There was no significant change in the frequency of urgency episodes, the delay in postponing defecation, or the number of bowel movements per week between the periods of stimulation. There was improvement in the Cleveland Clinic incontinence score from baseline but no statistically significant difference between scores in the ON compared to the OFF periods. Additionally, there was no correlation between changes in the frequency of urgency episodes, delay in postponing defecation, Cleveland Clinic score, and changes in anal resting pressure, maximal squeeze pressure, squeeze pressure duration, threshold, constant sensation, and maximum tolerated volumes between the baseline and final periods. No significant change in the maximum anal resting pressure, squeeze pressure increment, and duration of voluntary contraction was noted between the two stimulation periods. Data suggested a treatment effect in regards to the frequency of episodes with the use of SNS. Additionally, improvement was noted in incontinence scores from baseline compared to periods of stimulation results.

In a systematic review Jarrett et al. (2004) analyzed the safety and effectiveness of SNS for the treatment of fecal incontinence. Six patient series and one double-blind crossover study involving 266 patients who had failed maximum conservative therapy and had undergone peripheral nerve testing as a screen for SNS eligibility were assessed. Fifty-six percent of the patients underwent permanent SNS. Complete continence was reported in 41% to 75% of patients, and there was  $\geq 50\%$  improvement in the number of incontinence episodes in 75% to 100% of patients after permanent implantation. The assessment noted that overall, anal resting pressure does not appear to be significantly changed in patients with permanent SNS, but an increase in maximal squeeze pressure has been shown in some studies. Patients undergoing permanent implantation reported having 19 adverse events, including lead migration, pain, and infection. The authors note several study limitations including that most of the data reviewed came from patient series, rather than controlled studies, and follow-up is generally short-term. According to the authors, data was probably prospective but it was unclear from the reports. Additionally, no study compared SNS directly with another treatment for fecal incontinence or constipation. Nonetheless, the authors noted that evidence from the included studies suggested that permanent SNS substantially improves continence in patients with severe fecal incontinence resistant to medical treatment.

Although randomized controlled trial data are limited prospective and retrospective data suggest that sacral nerve stimulation (SNS) may improve the number of incontinence episodes and quality of life measures as reported by study participants. It is noted the number of adverse events reported in some studies is not insignificant with infection rates of 6–10.8%, and stimulator removal rates of 12%. However, SNS is considered an acceptable treatment for selected individuals with fecal incontinence.

### **Other Indications**

Less commonly SNS has been proposed for the treatment of various other conditions such as constipation and pelvic pain; however, data are limited and there is insufficient evidence in the peer-reviewed scientific literature to support safety and effectiveness (Maeda, et al., 2017, Pilkington, et al., 2017).

**Literature Review - Sacral Nerve Stimulation for Other Indications:** Zerbib et al. (2017) reported results of the CONSTIMOD (Efficacy of Sacral Nerve Modulation in Severe Refractory Constipation), a multicenter, randomized, double-blind, placebo-controlled, crossover study (n=36 patients). Adult patients were selected if they had chronic constipation for over one year defined by at least two of the following criteria: two or fewer complete bowel movements per week; straining to evacuate at  $> 25\%$  of attempts, or sensation of incomplete evacuation after defecation on  $> 25\%$  of occasions. Other criteria for selection included absence of symptomatic response to standard therapies for at least three months. Exclusion criteria were constipation secondary to anorectal malformation, neurological disorders and/or opiates; previous colorectal surgery of any type; or significant pelvic floor anatomical abnormality (e.g., rectocele, rectal prolapse). Responders to an initial three-week peripheral nerve evaluation (n=20) were offered permanent implantation of a pulse generator and assigned randomly in a crossover design to two eight-week intervals of active or sham stimulation. At the end of the two trial periods, the patients received active stimulation until the final evaluation at one year. The primary outcome measured was the proportion of patients with a response during each treatment period (stimulation on and off).

Response was measured over the last three weeks of each of the eight week treatment periods. Response to therapy was defined as at least three bowel movements per week and/or more than 50% improvement in symptoms. Secondary outcome measures included percentage of patients with a response at one year, effects of SNS on patients' daily bowel diary items, Wexner score, effect on QoL, visual analogue scale (VAS) score rating bowel habit, anorectal manometry parameters and colonic transit time. During the cross-over period, a positive response was observed in 12/20 and 11/20 patients after both active and sham stimulation periods, respectively ( $p=0.746$ ). There was also no statistically significant difference between on and off periods for any item of the daily stool diary, Wexner score, VAS score, or QoL scores. At one year of follow-up, 16/20 patients were available for assessment; a total of 11 patients had a sustained clinical response. SNS was found to be associated with a significant improvement in QoL for symptoms ( $p<0.001$ ), physical condition ( $p=0.003$ ) and emotions ( $p=0.004$ ). The mean difference in colonic transit times at baseline versus one-year follow-up was not found to be statistically significant ( $p=0.226$ ). A total of nine serious adverse events occurred in eight patients, related to, pain, infection or dysfunction of the device. Study limitations included, small sample size and loss to follow-up. These study results did not support the use of SNS for refractory constipation.

A Cochrane review of randomized or quasi-randomized trials ( $n=8$  studies) by Thaha et al. (2015) assessed the effectiveness of SNS using implanted electrodes for the treatment of fecal incontinence and constipation in adults. Of the eight trials, two cross over studies ( $n=61$  patients) assessed SNS for constipation. Patient in both studies underwent permanent SNS implantation following a three-week trial of temporary stimulation. Outcomes measured in studies included frequency of stools and constipation symptoms, as well as quality of life. In the larger trial (Dinning, et al. 2015 [ $n=59$  patients]), SNS did not improve frequency of bowel movements. Reported adverse effects (73) included pain at site of the implanted pulse generator (32), wound infection (12), and urological (17) events. The authors found limited evidence to suggest that SNS can improve fecal incontinence in a subset of patients. However, SNS was not found to improve symptoms in patients with constipation. Study results are limited by the number of studies and small sample sizes.

At present, the role of SNS for indications other than urinary urge incontinence, nonobstructive urinary retention, urinary urgency/frequency syndrome, and fecal incontinence has not been established.

#### **Professional Societies/Organizations**

**American College of Gastroenterology (ACG):** Wald et al. (2021) published guidelines regarding the management of benign anorectal disorders which included fecal incontinence. According to the ACG recommendations, "SNS can be recommended for patients with moderate to severe FI who have failed conservative measures, biofeedback, and other low-cost, low risk techniques". Grade of Recommendation: Strong recommendation based on low-quality evidence.

The guideline also mentioned that SNS has shown no benefit in treating constipation and cannot be recommended in patients with constipation of any type.

**American College of Obstetricians and Gynecologists (ACOG)/American Urogynecologic Society (AUGS):** The 2015 (reaffirmed 2022) joint ACOG/AUGS Practice Bulletin for urinary incontinence in women stated that sacral neuromodulation can be considered for patients with refractory urinary urge incontinence who have failed conservative treatment, including bladder training, pelvic floor physical therapy with biofeedback, and pharmacologic treatment.

**American Society of Colon and Rectal Surgeons (ASCRS):** The ASCRS issued a clinical practice guideline for the treatment of fecal incontinence which stated that SNS has been consistently shown to result in a reduction in frequency of FI episodes and may be considered as a first-line surgical option for incontinent patients with and without sphincter defects. Grade of Recommendation: Strong recommendation based on moderate-quality evidence (Paquette, et al., 2015).

The ASCRS clinical practice guideline for the evaluation and management of constipation stated that SNS may be an effective treatment for patients with chronic constipation and successful peripheral nerve evaluation test when conservative measures have failed; however, it is not currently approved by the US Food and Drug administration for this condition in the United States. Grade of Recommendation: Weak recommendation based on moderate quality evidence (Paquette, et al., 2016).

**American Urological Association (AUA)/Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU):** The 2014 AUA/ SUFU guideline on the diagnosis and treatment of non-neurogenic overactive bladder in adults addressed sacral neuromodulation as a treatment option. The guideline stated that sacral neuromodulation and peripheral tibial nerve stimulation may be offered as a third line treatment in a carefully selected patient population. For example, patients with severe refractory OAB symptoms or who are not candidates for second-line therapy and are willing to undergo a surgical procedure (Gormley, et al., 2012; Updated 2019).

### **Use Outside of the US**

According to the National Institute for Clinical Excellence (NICE) guideline on the use of sacral nerve stimulation for urge incontinence and urgency-frequency it is noted that the current evidence appeared adequate to support the use of this procedure. The diagnosis should be defined as clearly as possible and the procedure limited to patients who have not responded to conservative treatments such as lifestyle modifications, behavioral techniques and drug therapy. Patients should be selected on the basis of their response to peripheral nerve evaluation (NICE, 2004b, Updated 2012). In their guidance on SNS for idiopathic chronic non-obstructive urinary retention, NICE stated that the “current evidence on the safety and efficacy of sacral nerve stimulation for idiopathic chronic non-obstructive urinary retention is adequate to support the use of this procedure provided that normal arrangements are in place for clinical governance, consent and audit” (NICE, 2015). In their guidance on urinary incontinence and pelvic organ prolapse in women: management, NICE recommended offering “percutaneous sacral nerve stimulation to women after local or regional multidisciplinary teams (MDT) review if their overactive bladder has not responded to non-surgical management including medicines and: their symptoms have not responded to botulinum toxin type A or they are not prepared to accept the risks of needing catheterization associated with botulinum toxin type A” (NICE 2019).

On behalf of the International Consultation on Urologic Disease, Abrams et al. (2018) published the Sixth International Consultation on Incontinence, Recommendations of the International Scientific Committee: Evaluation and Treatment of Urinary Incontinence, Pelvic Organ Prolapse, and Fecal Incontinence. Regarding fecal incontinence the Consultation noted “The surgical approach to the incontinent patient is dictated by the presence and magnitude of an anatomical anal sphincter defect. If no defect is present, or if the sphincter defect is minimal, options include SNS and biomaterial injection therapy.”

The recommendations further noted “for patients with moderate sphincter defects, sphincteroplasty, SNS or biomaterial injection therapy can each be considered. For patients with large sphincter defects (> 120 degrees), sphincteroplasty is likely to be the best option, though a PNE trial for SNS can be considered. Patients with sphincter defects of greater than 180 degrees or major perineal tissue loss require individualized treatment. In some cases, initial reconstruction can be performed. Should incontinence persist, alternatives include stimulated muscle transposition, artificial anal sphincter implantation, or SNS. For patients who remain incontinent following sphincteroplasty, repeat endoanal ultrasound should be undertaken to reassess the status of the repair. If no defect is present or if the sphincter defect is minimal, options include SNS and biomaterial injection therapy”. Patients who have failed sacral nerve stimulation can be considered for sphincteroplasty if a sphincter defect is present.”

Regarding the use of sacral nerve stimulation (SNS) for the treatment of fecal incontinence, the National Institute for Clinical Excellence (NICE) (2007; updated 2018) noted, “A trial of temporary SNS should be considered for people with fecal incontinence in which sphincter surgery is deemed inappropriate. These may be patients with intact anal sphincters, or those with sphincter disruption. In those with a defect, contraindications to direct repair may include atrophy, denervation, a small defect, absence of voluntary contraction, fragmentation of the sphincter, or a poor-quality muscle.” “All individuals should be informed of the potential benefits and limitations of this procedure and should undergo a trial stimulation period of at least two weeks to determine if they are likely to benefit. People with fecal incontinence should be offered SNS on the basis of their response to percutaneous nerve evaluation during specialist assessment, which is predictive of therapy success.”

### **Percutaneous Tibial Nerve Stimulation (PTNS)**

## Overactive Bladder

The Urgent® PC Neuromodulation System (Uroplasty, Inc., Minneapolis, MN) is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. It is performed in a physician office. The method of treatment is referred to as percutaneous tibial nerve stimulation (PTNS). The mechanism of action in neuromodulation of the bladder is not precisely understood, but neuromodulation likely interrupts abnormal reflex neurologic arcs, thus improving coordination of the detrusor and sphincter muscles. The majority of research in percutaneous tibial nerve stimulation (PTNS) has been for the treatment of overactive bladder (OAB) syndrome, defined as urinary urgency, usually accompanied by frequency and nocturia, with or without urgency urinary incontinence, in the absence of urinary tract infection or other obvious pathology (Haylen, et al., 2010). PTNS was developed as a less-invasive alternative to sacral nerve stimulation. A needle electrode is inserted at a depth of 3–4 cm near the tibial nerve at the medial malleolus. The needle is connected to a low-voltage, adjustable, hand-held stimulator, which sends an electrical impulse through the tibial nerve. The protocol for initial treatment typically consists of weekly 30-minute treatment sessions for 12 weeks. The protocol for maintenance PTNS treatment is less well defined, but will typically be done every three to four weeks after a beneficial response to the initial 12 week treatment (Kirby and Lentz, 2017).

**U.S. Food and Drug Administration:** Urgent® PC Neuromodulation System (Uroplasty, Inc., Minneapolis, MN) was FDA-approved October 2005. The Urgent PC Neuromodulation System delivers PTNS, and is intended to treat patients with overactive bladder and associated symptoms of urinary urgency, urinary frequency, and urge incontinence. In 2010 Urgent® PC Neuromodulation System (Uroplasty, Inc., Minnetonka, MN), received 510K approval as a substantially equivalent device with changes to the indication statement. The device is “intended to treat patients with overactive bladder (OAB) and associated symptoms of urinary urgency, urinary frequency, and urge incontinence”. In 2015, Uroplasty Inc was merged into Cogentix Medical.

NURO Neuromodulation System was FDA-approved November 2013. The NURO Neuromodulation System is substantially equivalent to the Urgent PC Neuromodulation System and is “intended to treat patients with Overactive Bladder (QAB) and associated symptoms of urinary urgency, urinary frequency, and urge incontinence”.

**Literature Review - Percutaneous Tibial Nerve Stimulation (PTNS) for Overactive Bladder:** PTNS has been evaluated primarily for overactive bladder syndrome in RCTs and systematic reviews/meta-analysis. There is sufficient evidence to support improved clinical outcomes using PTNS for the treatment of OAB and continued monthly maintenance therapy if there is a beneficial clinical response to the standard treatment regimen of 30-minute weekly sessions for 12 weeks (Salatzki, et al, 2019; Yoong, et al., 2013; Van der Pal, et al., 2006).

In a prospective cross-sectional cohort study Salatzki et al. (2019) assessed the factors influencing return for maintenance percutaneous tibial nerve stimulation (PTNS) treatment after successful completion of a 12-week course of PTNS treatment for overactive bladder (OAB). Included patients (n=83) experienced OAB symptoms and underwent 12 sessions of weekly PTNS treatment. Patients were evaluated at baseline and at week 12 using the International Consultation on Incontinence Questionnaire on OAB, the International Consultation on Incontinence Questionnaire on lower urinary tract symptom-related quality of life (ICIQ-LUTSqol) and a bladder diary (BD). Following treatment, patients (n=73) were placed into three groups: group 1 (n=25) did not respond to 12 weekly sessions of PTNS treatment; group 2 (n=17) responded to treatment but did not return for maintenance treatment and group 3 (n=31) responded to treatment and returned for maintenance treatment. Responders to treatment, evaluated using two patient-reported outcome measures, were invited to return for maintenance treatment when symptoms returned. The study measured factors influencing adherence to maintenance treatment after 12 sessions of PTNS treatment using a PTNS Service Evaluation Questionnaire. Patients belonging to groups 2 and 3 experienced a significant improvement from baseline to week 12 in total OAB scores ( $p<0.05$ ). However, patients returning for maintenance treatment reported significant improvements specifically in nocturia (BD difference and ICIQ-LUTSqol difference,  $p<0.05$ ,  $p<0.05$ , respectively) and perceived benefits of the treatment with regard to their OAB symptoms compared to those not returning for maintenance treatment (difference between the two groups 25.6%;  $p=0.030$ ). Improvements in nocturia and perceived benefits predicted return for maintenance treatment based on a logistic regression analysis. Factors related to the need for repeat clinic visits, such as transportation, distance and time commitment, were not found to differ between the two groups. Author noted limitations included a small patient population, unbalanced subgroups and the

results may not be reproducible in other healthcare models. The authors concluded that 12-session weekly PTNS is a safe and effective treatment for OAB. Responders to treatment returning for maintenance PTNS reported significant improvements in nocturia and perceived benefits over time, compared to those not returning for maintenance treatment.

Vecchioli-Scaldazza et al. (2018) performed a randomized controlled trial to assess effectiveness and durability of an antimuscarinic medication (group A) versus percutaneous tibial nerve stimulation (group B) versus combination therapy (group C) in women with overactive bladder syndrome (OAB). The study included women (n=105) with symptoms of overactive bladder (urgency, urinary frequency, with or without urge incontinence). Patients were divided randomly into three groups of 35 patients each. Patients in Group A received antimuscarinic medication daily for 12 weeks. In Group B patients underwent PTNS once a week for 30 minutes each for a total of 12 weeks. In Group C patients underwent PTNS once a week for 30 minutes each for a total of eight weeks and antimuscarinic medication on alternate days also for eight weeks. The primary endpoint measured improvements in OAB symptoms, including day time frequency, night time frequency, urgency and urge incontinence. The impact of OAB symptoms on patient's quality of life (QoL) and the patient impression of improvement were the measured secondary endpoints. A total of 27/35 patients completed the study. Combination therapy provided a clinically significant difference when compared to antimuscarinic medication in treating daily and night time micturition ( $p=0.0167$ ). Combination therapy significantly reduces Urgency and urge incontinence compared to antimuscarinic medication and percutaneous tibial nerve stimulation ( $p=0.0005$ ;  $p=0.0225$  and  $p=0.0003$ ;  $p=0.0015$  respectively). Significant improvements in quality of life of patients (OAB-q SF, 6 and 13 items) were found after treatment in all groups evaluated. Adverse events were not reported. Author acknowledged limitations included the small patient population and the short term follow-up of ten months. The study concluded that the combination of antimuscarinic medication and PTNS in the treatment of OAB symptoms was an effective and well-tolerated therapy with greater improvements and longer lasting effects than single treatments.

Vecchioli-Scaldazza et al. (2013) performed a randomized controlled crossover study (n=40) of women with OAB treated with PTNS or antimuscarinic medication. Exclusion criteria included stress incontinence, urinary tract infection, neurological disease, genital prolapse, uncontrolled narrow angle glaucoma, pelvic tumors or those previously treated with pelvic surgery, radiation therapy or antimuscarinic agents. Group A (n=20) received antimuscarinic medication daily for 40 days and underwent PTNS after three months from the end of therapy (i.e., washout period). PTNS treatment was given 30 minutes, twice a week for a total of six weeks. In group B (n=20), the women underwent PTNS as previously described and received antimuscarinic medication as above three months after the end of treatment. A total of 30/40 patients (75%) completed the study. The number of daily voids significantly decreased after each treatment compared to baseline. In group A, the mean number of daily voids pre- and post-medication differed significantly (medication  $p=0.004$ ; PTNS  $<0.001$ ). Similarly in group B, there was a statistically significant difference in pre- and post- treatment voids (medication  $p=0.008$ ; PTNS  $<0.001$ ). Secondary outcomes of nocturia, urge incontinence, and voided volume, also significantly improved after each treatment, with no significant differences between interventions. Study limitations included small sample size and loss to follow-up, however these short-term results suggest that PTNS is at least equivalent to antimuscarinic therapy for treating OAB symptoms.

Gungor et al. (2013) published results of an RCT (n=59) comparing transvaginal electrical stimulation (n=38) and PTNS (n=21) in women with OAB. Inclusion criteria were symptoms of OAB and detrusor overactivity. Exclusion criteria included pregnancy, cardiac disorders, neurological disorders, vesicoureteral reflux, menorrhagia, urinary tract infection or vaginitis, pelvic organ prolapse, and presence of an intrauterine device. The electrical stimulation protocol given to group one consisted of 20-minute treatments three times per week for six to eight weeks. PTNS was performed in group two with an Urgent PC device used for twelve 30-minute weekly sessions. A total of 52 of 59 (88%) patients completed the study. The groups did not differ significantly for outcomes of change in urgency, nocturia or incontinence episodes from baseline to the end of the treatment period. There was a statistically significant difference in daytime frequency ( $p=0.03$ ). Study limitations included small sample size and participants lost to follow-up. Study results suggested that ES and PTNS may be equally effective in reducing symptoms of OAB.

An RCT by Peters et al. (2013) reported safety and efficacy results of PTNS for overactive bladder after three years of therapy. Patients (n=50) in the randomized, double-blind SUMiT (Sham Effectiveness in Treatment of

Overactive Bladder Symptoms) Trial who met the primary effectiveness end point after 12 weekly percutaneous tibial nerve stimulation treatments were enrolled in this prospective study to assess long-term outcomes. Subjects in this STEP (Sustained Therapeutic Effects of Percutaneous Tibial Nerve Stimulation) Study were prescribed a fixed schedule 14-week tapering protocol followed by an individual treatment plan aimed at sustaining overactive bladder symptom improvement. A total of 29 patients completed the 36-month protocol. Statistical analysis estimated that 77% of patients maintained moderate or marked improvement in overactive bladder symptoms at three-year follow-up. Compared to baseline, the frequency of median voids per day, urge incontinence episodes, and nighttime voids, decreased significantly (all  $p < 0.0001$ ). All quality of life parameters remained markedly improved from baseline through three years ( $p < 0.0001$ ). Limitations of this study include the small patient population and loss to follow-up. The authors concluded that most patients with an initial positive response to 12 weekly percutaneous tibial nerve stimulation treatments safely sustained overactive bladder symptom improvement to three years with an average of one treatment per month.

The Agency for Healthcare Research and Quality (AHRQ) published a 2012 comparative effectiveness review of nonsurgical treatments for urinary incontinence in adult women. The clinical effects of PTNS were examined in four RCTs that compared PTNS and no active treatment in patients with OAB. The longest follow-up time period was 12 weeks. The AHRQ report provided a pooled analysis of data from three studies ( $n=405$  patients) that found statistically significantly greater improvement in urinary incontinence in the PTNS compared to control group (RR: 1.9, 95% CI: 1.1 to 3.2). Evidence from one study was insufficient to conclude better effectiveness of PTNS compared to medication. No RCTs compared continence after PTNS versus sham stimulation beyond 12 weeks. Evidence from one study was insufficient to conclude better effectiveness of PTNS compared to medication. The study results indicated that PTNS improved urinary incontinence compared to sham treatment in the short-term (Shamliyan et al., 2012).

A systematic review and meta-analysis ( $n=16$  studies/940 subjects) by Burton et al. (2012) evaluated the effectiveness of posterior PTNS in treating overactive bladder symptoms. Studies included RCTs ( $n=6$ ), and prospective, non-comparative studies ( $n=10$ ). PTNS was compared to sham in four RCTs showing a significant difference favoring PTNS [RR 7.02 95% confidence interval (CI) 1.69-29.17]. PTNS was compared to anticholinergic medication in two RCTs with no significant difference in the change in bladder diary parameters between the treatments. The pooled subjective success rate was 61.4% (95% CI 57.5-71.8) and objective success rate was 60.6% (95% CI 49.2-74.7). Although there was evidence of significant improvement in overactive bladder symptoms comparable to the effect of anticholinergic medication, the studies included in the review only considered short-term outcomes after initial treatment. The review summarized that in order to recommend PTNS as a practical treatment option, long-term data and health economic analysis are needed.

Monga et al. (2012) performed a systematic review of the evidence for a range of electrical stimulation therapies in the treatment of lower urinary tract symptoms. Of the 72 studies reviewed, a total of 16 evaluated PTNS. These included prospective case series ( $n=13$ ) and randomized comparative studies ( $n=3$ ). Findings indicated that median mean reductions in incontinence episodes and voiding frequency were similar for implanted SNS and PTNS, with median mean values of 72 and 66% for incontinence episodes and median mean values of 40 and 32.5% for voiding frequency for SNS and PTNS, respectively. However it was determined that additional long-term follow-up studies are needed to validate the ability of this therapy to produce sustained benefit (Monga, et al., 2012). Additional systematic reviews without meta-analysis (Moossdorff-Steinhauser, et al., 2013; Gaziev, et al., 2013; Biemans, et al., 2013; Levin, et al., 2012) included the same RCTs and draw similar conclusions that limited high quality data demonstrated that PTNS is an effective and safe option to treat OAB patients, but further studies are needed to assess the long term durability of the treatment.

Peters et al. (2010) conducted a RCT comparing the efficacy of PTNS to sham through 12 weeks of therapy. The eligibility criteria included a score of at least four on the overactive bladder questionnaire (OAB-q) short form for urgency, self-reported bladder symptoms lasting at least three months, and failure of conservative management. A total of 220 patients were randomized, 110 to the PTNS group and 110 to the sham group. Females accounted for 86 (78.2%) of the PTNS subjects and 88 (80.0%) of the sham subjects. The sham group underwent stimulation through a TENS unit with no needle insertion. Both groups received 12 weekly 30-minute intervention sessions. The 12-week course of treatment was completed by 103 of 110 (94%) in the PTNS group and 105 of 110 (95%) in the sham group. Global response assessment (GRA) at 13 weeks compared to baseline for overall bladder symptoms improvement demonstrated 60/103 (58.3%) for PTNS and 23/105 (21.9%) for sham

( $p < 0.001$ ). This is statistically significant. In total, six PTNS subjects reported nine mild or moderate treatment related adverse events consisting of ankle bruising (1 of 110, 0.9%), discomfort at the needle site (2 of 110, 1.8%), bleeding at the needle site (3 of 110, 2.7%) and tingling in the leg (1 of 110, 0.9%). No local treatment related adverse events were reported in the sham group. In addition, no systemic adverse events were experienced in either group. The authors concluded that PTNS therapy is safe and effective in treating OAB symptoms. Limitations of the SUMiT trial included the primary outcome measured used was a single response, patient-reported global response assessment (GRA) and there was short follow-up of three months.

Finazzi-Agro et al. (2010) also performed a RCT comparing PTNS with a sham. A total of 35 female patients presenting with detrusor overactivity incontinence that did not respond to anti-muscarinic therapy were randomly assigned to percutaneous tibial nerve stimulation or to a control group. The percutaneous tibial nerve stimulation group (18 patients) was treated with 12 percutaneous tibial nerve stimulation sessions. The control group (17 patients) received an original placebo treatment using a 34 gauge needle placed in the medial part of the gastrocnemius muscle. Patients showing a reduction in urge incontinence episodes greater than 50% were considered responders. PTNS was performed three times per week for four weeks. The primary outcome for this study was the percent responders, defined as a greater than 50% reduction in incontinent episodes. This endpoint was reached by 71% (12/17) of patients in the PTNS group, compared with 0% (0/15) in the placebo group ( $p < 0.001$ ). No serious side effects were reported in either group but patients in both groups reported occasional transient pain at the stimulation site. Study limitations included small patient population and short follow-up.

In an RCT, Peters et al. (2009) compared the effectiveness of a series of 12 weekly, 30-minute office based PTNS treatments and 12 weeks of 4 mg daily extended-release tolterodine tartrate (Detrol® LA). Included were ambulatory adults with overactive bladder (OAB) symptoms, with or without a history of previous anticholinergic drug use, with at least eight voids per 24 hours documented by history and physical and voiding diary. Females made up 90% of the participants. Of the patients who completed 12 weeks of therapy, 41 of 44 receiving PTNS and 43 of 43 on tolterodine completed the voiding diary. Using the Global Response Assessment (GRA), subject assessment of OAB symptom improvement compared to baseline was dramatically greater in the PTNS arm with 79.5% reporting cure or improvement compared to 54.8% of subjects on tolterodine ( $p = 0.01$ ). This global assessment of improvement may have been greater because subjects in the PTNS arm may have had less significant side effects or more perceived improvement in subjective changes such as urgency, or because of the novel nature of the treatment. Limitations of this study included: industry-sponsored; no sham/placebo control group; potential for observation bias (PTNS group assessed in-person, tolterodine group assessed by phone). After 12 weeks, subjects randomized to weekly PTNS were offered an additional nine months of treatment with assessments at six and 12 months from baseline (MacDiarmid, et al., 2010). A total of 33 PTNS responders continued therapy with 32 and 25 subjects completing six and 12 months of therapy, respectively. Subjects received a mean of 12.1 treatments during an average of 263 days, with a median of 17 days between treatments. At six months 94% of subjects classified OAB symptoms as improved from baseline and 96% reported improvement at 12 months. Overactive bladder questionnaire symptom severity was significantly improved from 12 weeks to 12 months ( $p < 0.01$ ) as well as from six to 12 months ( $p < 0.01$ ). No serious adverse events occurred. Limitations included: no control group; the definition of response used was not standardized and based entirely on a GRA; there was not a standardized treatment protocol as patients returned for maintenance therapy at irregular intervals as dictated by patient preference. There is sufficient evidence in the peer-reviewed scientific literature to support the short-term safety and efficacy of PTNS as a treatment for OAB symptoms.

## **Fecal Incontinence and Constipation**

Percutaneous posterior tibial nerve stimulation (PTNS) is a peripheral neuromodulation technique that has most recently been proposed for the treatment of fecal incontinence and constipation. Percutaneous PTNS delivers electrical current via a small needle electrode unilaterally inserted in the ankle, above the medial malleolus, into a superficial branch of the posterior tibial nerve. A low voltage electrical impulse travels up the posterior tibial nerve to the sacral nerve plexus to alter pelvic floor function. The procedure is typically performed in the provider's office for 6–12 sessions, for 30 minutes, one to two times a week.

The overall body of literature reports that there is insufficient evidence to draw conclusions regarding the effectiveness of percutaneous PTNS for the treatment of fecal incontinence and constipation. Studies are of low

quality with small patient populations and short-term follow-ups. Optimal treatment protocol including duration, stimulation frequency/rhythm and repeat/maintenance treatment have not been established. (Moya, et al., 2016; Peña, et al., 2016; Wald, et al., 2016; Benezech, et al., 2016; Kumar, et al., 2016; Edenfield, et al., 2015; Whitehead, et al., 2015; Barker and Hurley, 2014; George, et al., 2013).

**U.S. Food and Drug Administration:** Currently, there is no device that is FDA approved for percutaneous PTNS for fecal incontinence. Studies have reported the use of the Urgent® PC Neuromodulation system (Uroplasty Inc., Minnetonka, MN) which FDA approved for the treatment of overactive bladder (OAB) and associated symptoms of urinary urgency, urinary frequency, and urge incontinence (FDA, 2010).

**Literature Review - Percutaneous Tibial Nerve Stimulation (PTNS) for Fecal Incontinence and Constipation:** There is insufficient evidence to support the effectiveness of percutaneous PTNS for the treatment of fecal incontinence and constipation. Although improvement in incontinence has been reported, the quality of the evidence is low. Studies have primarily been in the form of case series with small patient populations (n=10–144) and short-term follow-ups (4–12 weeks). Outcomes are conflicting and some comparative studies reported no significant improvement in fecal incontinence compared to sham. Typically, when improvements were reported, they were not maintained and maintenance therapy was required. Established initial treatment regimens and maintenance regimens for fecal incontinence have not been defined (Manso, et al., 2020, Rodríguez Carrillo, et al., 2019).

Zyczynski et al. (2022) conducted a randomized controlled trial (RCT) that assessed whether percutaneous tibial nerve stimulation (PTNS) is superior to sham stimulation for the treatment of fecal incontinence (FI) in women refractory to first-line treatments. Women (n=166) aged 18 years or older with ≥ 3 months of moderate-to-severe FI that persisted after a 4-week run-in phase were randomized 2:1 (PTNS: sham stimulation) to 12 weekly 30-minute sessions. Women in the PTNS group (n=111) received stimulation to a single lower extremity in 12 weekly 30-minute sessions, while the sham group (n=54) received stimulation without delivering a therapeutic effect. The primary outcome measured the patient reported change from baseline FI using the St. Mark patient assessment score after 12 weeks of treatment. The secondary outcomes measured the frequency of bowel events, FI episode-free days and quality of life. The patients in the study were primarily White (80.7%) and overweight or obese (76.2%). Before randomization, participants reported 13.3 (67.3) bowel movements and 6.6 (65.5) leaks per week, of which half were associated with urgency. The study reported no significant difference between the groups in the improvement of fecal incontinence, weekly frequency and FI episode-free days. Additionally, both groups reported high levels of symptom control with no group difference in perceived improvement. Condition-specific quality of life measures did not indicate a benefit of PTNS over sham stimulation. Compared with sham stimulation group, the PTNS group reported significantly greater improvement in 3 of 4 subscales of the Fecal Incontinence Quality of Life Scale for the Lifestyle, Depression/ Self-perception, and Embarrassment scores. Serious adverse events occurred in 4% of each group. The authors noted that the findings of the study are limited to women, many seeking care for pelvic floor disorders at urogynecology clinics, and to the protocol-specified frequency and duration of PTNS sessions. Results should not be inferred to men who are equally affected by FI. The authors concluded that although symptom reduction after 12 weeks of PTNS met a threshold of clinical importance, it did not differ from sham stimulation. The study findings do not support the general use of PTNS in women with FI refractory to exercise and medication therapy.

Marinello et al. (2021) conducted a multicenter, double-blind randomized controlled trial (RCT) that assessed the efficacy of PTNS compared to sham stimulation in patients with severe low anterior resection syndrome (LARS). Adults aged 19–75 years, who had undergone anterior resection of the rectum with sphincter preservation for rectal cancer, and who had received definitive surgery at least one year previously (rectal resection or ileostomy closure), with major LARS were included in the study. The study included 16 sessions of 30 min once a week for 12 consecutive weeks, followed by four additional sessions once every two weeks for the following 4 weeks. The primary outcome measured the efficacy of PTNS using the LARS score 12 months after treatment. The LARS score is an internationally validated, self-administered questionnaire used to assess bowel function after anterior rectal resection. Secondary outcomes included fecal incontinence, quality of life (QoL) and sexual function. Patients (n=46) were randomly assigned in a 1:1 ratio to PTNS (n=23) or sham therapy (n=23). Following treatment, follow-up occurred during a clinical visit after one, three, six, and 12 months. Ten patients were lost to follow-up (n=2/PTNS group; n=8/sham group). No deaths were reported during follow-up. LARS scores were reduced in both groups, but only patients who received PTNS maintained the effect at 12 months (p=0.018). The



fecal incontinence score was significantly improved after 12 months in the PTNS group at 12 months ( $p=0.018$ ). No major changes in QoL and sexual function were observed in either group. The study concluded that PTNS could have positive effects in some patients with LARS, but its clinical significance might be limited. Additional randomized controlled trials with larger patient populations and long-term follow-up are needed to support the outcomes of this study. A limitations of the study included that the population only included patients from Barcelona, Spain and the results may not be applicable to other races or ethnic groups.

van der Wilt et al. (2017) reported results of a multicenter, single-blinded, parallel sham-controlled trial that evaluated the effects of percutaneous tibial nerve stimulation (PTNS) using Urgent® PC Neuromodulation System (Uroplasty, Geleen, The Netherlands) in the treatment of fecal incontinence (FI). Patients ( $n=59$ ) were randomized into two groups, PTNS ( $n=29$ ) or sham ( $n=30$ ), for nine weeks. Patients were included if they were referred to the centers' outpatient clinics reporting FI of solid or liquid stool causing significant disruption to lifestyle, and were at least 18 years old. Patients also needed to show failure of conservative treatment for at least six months, be psychologically stable, able to understand (read and write) and willing to adhere to the requirements of the trial. Patients were required to have a minimum of three FI events over a three week period before starting treatment, which was documented in a bowel diary. Lastly, patients needed to have proper sensory and motor response in order to participate in PTNS. The primary outcome measured the response to treatment based on the median number of FI episodes per week which was assessed over three weeks. Secondary outcomes included measures of FI symptom severity along with disease-specific and generic quality of life (QoL). After nine weeks, the treatment allocation was disclosed to the patients. Those who had been receiving sham treatment were offered PTNS, whereas those allocated to PTNS were able to continue with this treatment. Outcome assessments were obtained after six and 12 months of follow-up in patients still receiving treatment. Two patients in the PTNS group were lost to follow-up. After nine weeks of treatment, a clinically significant 50% or greater reduction in the median number of FI episodes per week was observed in 13/29 patients in the PTNS group compared with 6/30 in the sham treatment group ( $p=0.028$ ). However, when the response to treatment was based on at least a 50% reduction in the mean number of FI episodes per week, the difference between groups was no longer significant ( $p=0.347$ ). Scores on the Cleveland Clinic Florida fecal incontinence scale decreased significantly in both groups, but more steeply in the PTNS group ( $p=0.049$ ). The aggregated mental component score improved in the PTNS but not in the sham group ( $p=0.028$ ). Over the nine week treatment period, three treatment/device-related mild adverse events were reported in the PTNS group. One patient reported pain at the puncture site that subsided after the treatment session. Another patient reported pain in the ankle and another reported bruising in the ankle; both events subsided within one week. In the sham group, one patient reported lower abdominal pain. Limitations of the study included relatively large differences in the number of FI episodes/week between the groups at baseline, small sample size and potential patient bias because it is difficult to blind patients completely to the sensation of electrical stimulation. The authors concluded that the results have not established the value of PTNS compared to sham. Further studies with meta-analyses of individual participant data are indicated.

Edenfield et al. (2015) conducted a systematic review of the literature to assess the safety and effectiveness of cutaneous and percutaneous PTNS for the treatment of fecal incontinence. Regarding percutaneous PTNS, one randomized controlled trial (George, et al., 2013 discussed below) and eight case series met inclusion criteria. Outcomes included self-reported bowel diary information and results of the studies generally reported improvement in fecal incontinence and bowel movement deferment time. Quality of life outcomes (coping, embarrassment, depression, general health) varied and were conflicting. The evidence was insufficient to assess the effect on quality of life and anorectal manometry outcomes. Adverse events were uncommon and not serious. Maintenance sessions ranged from 1–40 months. Overall study quality was “poor” based on the study design and several of the trials were pilot studies. Meta-analysis was not possible due to heterogeneity of outcome reporting and variability of type of PTNS used and the lack of long-term data. There is a paucity of data re maintenance therapy. Limitations of the studies included: small patient populations (16–115), short-term follow-ups (6–12 weeks) and lack of a comparator. Outcomes and techniques used in the studies were inconsistent. The clear and ideal treatment and maintenance regimens for percutaneous PTNS are not established. Well-designed randomized controlled trials are needed to evaluate the effectiveness of percutaneous PTNS with conventional therapies.

In a 2015 randomized controlled trial (Knowles, et al.) assigned patients to percutaneous PTNS ( $n=115$ ) or sham ( $n=112$ ). This study, the CONtrol of Faecal Incontinence using Distal Neuromodulation [CONFIDeNT]), was a

double-blind, multicenter study involving 17 centers. Subjects, aged 18 years or older, had substantial fecal incontinence, refractory to conservative treatments (e.g., dietary changes and pelvic floor exercises). Patients were randomized to percutaneous PTNS or sham. The primary outcome was a clinical response to treatment defined as a 50% or greater reduction in episodes of fecal incontinence per week. The outcome was assessed using data from patients' bowel diaries after 12 treatment sessions which were administered once a week. The Urgent PC neuromodulation system (Uroplasty, Minnetonka, MN) was used for PTNS. This system is not FDA approved for the treatment of fecal incontinence. Twelve patients withdrew from the study. Patients completed three bowel diaries recording the number of incontinent bowel movements per day. There was no significant improvement in fecal incontinence with percutaneous PTNS over sham therapy. In the treatment group, a total of 39/103 (38%) patients had full data from bowel diaries and had a 50% or greater reduction in the number of episodes of fecal incontinence per week compared with 32/102 (31%) of patients in the sham group ( $p=0.396$ ). The mean total episodes of fecal incontinence per week in the PTNS group were significantly decreased compared to sham ( $p=0.02$ ) and there was a significant reduction in mean number of episode of urge incontinence ( $p=0.02$ ) but not passive incontinence ( $p=0.23$ ). The author noted that the clinical interpretation of these improvements was unknown. There were no significant improvements for generic quality-of-life measures or use of loperamide. There were seven mild adverse events related to pain at the needle site. Based on this data, the authors did not recommend percutaneous PTNS for the treatment of fecal incontinence.

Horrocks, et al. (2014) conducted a systematic review to evaluate the safety and efficacy of posterior tibial nerve stimulation for the treatment of fecal incontinence. One randomized controlled trial (George, et al., 2013) and five studies related to percutaneous PTNS met inclusion criteria. The primary outcome measure was an improvement of at least 50% in the number of incontinent episodes. Secondary outcome measures included: reduction in weekly incontinent episodes, cure rates, improvement in incontinence scores and improvement in quality-of-life (QoL) measurements. The proportion of patients who reported a reduction in fecal incontinence episode of at least 50% ranged from 63%–82%. Five studies reported improvement in QoL after treatment, especially in depression, coping/behavior, embarrassment and lifestyle. However, different methods were used to collect the data. Limitations of the studies included: small patient populations, short-term follow-up, heterogeneity of treatment protocol and variation in outcomes.

George et al. (2013) conducted a single-blind, randomized controlled trial ( $n=29$ ) to evaluate the effectiveness of percutaneous PTNS for the treatment of fecal incontinence (FI). Patients, > age 18 years, with at least two or more episodes of FI per week who had failed maximal pharmacological and behavioral therapy were included. The mean duration of incontinence was 55 (SD  $\pm$  22) months. The majority ( $n=23$ ) of the patients had mixed urge and passive fecal incontinence. Subjects were divided into three groups. Group 1 ( $n=11$ ) was treated with percutaneous PTNS; group 2 ( $n=10$ ) with transcutaneous PTNS (TENS) and group 3 ( $n=8$ ) with sham transcutaneous PTNS. Each group was treated twice-weekly in 30 minute sessions for six weeks. The percutaneous PTNS electrostimulation was delivered using the Urgent PC Uroplasty stimulation system which is not FDA approved for this indication. The primary outcome was response to treatment defined as  $\geq 50\%$  reduction in FI episodes per week compared to baseline. Secondary outcomes included changes in the number of continent days, fecal urgency, and quality of life scores. Patients who had a reduction of at least a 50% in incontinence at the end six weeks were followed up for a further six months and given follow-up therapy as needed. Nine group 1 patients, five group 2 patients and one group 3 patient reported  $\geq 50\%$  reduction in FI ( $p=0.035$ ) and became fully continent at the end of the study period. At six months 7/9 patients in group 1 remained asymptomatic, two patients had a loss of efficacy after three months. All five patients in group two and the single patient in group 3 remained asymptomatic. There was no appreciable difference in rectal sensory perception between the three groups. During stimulation, two patients reported two episodes each of mild self-limiting cramping abdominal pain. Limitations of the study include: lack of a control group for percutaneous PTNS, small patient population, short-term treatment and follow-up, and fewer patients in the sham group. The authors noted that the study was powered only to identify a difference between the three groups and not for specific comparison between pairs of study groups.

### **Implantable Tibial Nerve Stimulation**

There are several implantable tibial nerve stimulation devices (eCoin<sup>®</sup>, RENOVA<sup>™</sup> iStim system, Bioness StimRouter System) that are being studied for the treatment of urinary tract dysfunction (e.g., overactive bladder, urinary urge incontinence).

These devices are surgically implanted in the posterior tibial nerve area and stimulated externally. The eCoin, a miniaturized leadless neurostimulator was recently approved by the FDA. The eCoin is inserted near the ankle, above the tibial nerve using only local anesthetic and is proposed to provide automatic, intermittent tibial nerve stimulation to reduce urge urinary incontinence without patient remote management (Valencia Technologies, Inc, 2022).

**U.S. Food and Drug Administration:** According to the FDA, eCoin® Peripheral Neurostimulator (Valencia Technologies Corporation, CA) received premarket approval (PMA) on July 15, 2022. Per the FDA the eCoin® Peripheral Neurostimulator “is indicated to treat urgency urinary incontinence in patients intolerant to or having an inadequate response to other more conservative treatments or who have undergone a successful trial of percutaneous tibial nerve stimulation.” According to the FDA summary of safety and effectiveness data (SSED), two post-approval studies (PAS) are required. The first is continued follow-up of the “Pivotal Study of Subcutaneous Tibial Nerve Stimulation with eCoin® for OAB with Urinary Urge Incontinence” and report clinical outcomes, including all device-or procedure-related adverse events to FDA through five years post-implantation. The second is a prospective, single-arm, multi-center, observational study designed to collect effectiveness and safety data in a post-approval setting. Effectiveness will be determined at 12 and 24 months and continue to be collected for five years post-implantation of study subjects (FDA, 2022)

**Literature Review:** The overall body of literature reports that there is insufficient evidence to draw conclusions regarding the effectiveness of implantable tibial nerve stimulation for the treatment of urinary voiding dysfunction, fecal incontinence and constipation. Studies are of low quality with small patient populations and short-term follow-ups (Kaaki, et al., 2022; Gilling, et al., 2021; Rogers, et al., 2021; Dorsthorst, et al., 2020).

Rogers et al. (2021) conducted a prospective, open-label, single arm trial that evaluated the safety and efficacy of the eCoin® for the treatment of refractory urgency urinary incontinence (UUI). Adults aged 18–80 with daily UUI who were intolerant or had an inadequate response to, at least one second or third-line therapy prior to enrollment were included in the study. One-hundred thirty-seven patients had the eCoin implanted subcutaneously using only local anesthetic in the medial lower leg above the fascia. Four weeks after implantation with minimal swelling confirmed, the device was activated. The eCoin delivered automated stimulation sessions for the duration of the study. Automated stimulation sessions occur for 30-minute durations every three days for 18 weeks and every four days thereafter. The primary outcomes measured the efficacy and safety of the device. Efficacy was measured by the proportion of patients who achieved a 50% or greater reduction from baseline in urgency urinary incontinence episodes after 48 weeks of therapy. Safety outcome measured device-related adverse events at the same time point. After activation, patients had follow-up visits at four, eight, 12, 24, 36 and 48 weeks. At each follow-up, a 3-day voiding diary was collected and the OAB Questionnaire, Patient Global Impression of Improvement, and a custom Likert scale on subject satisfaction questionnaires were administered. Patients were questioned about adverse events, initiation of OAB medications, any other changes to their history or comments regarding the device. Reprogramming was offered at the eight, 24 and 36-week visits. At 48 weeks post-activation, participants replied to a non-validated questionnaire detailing their experience with the device, implant procedure and their attitudes towards eCoin compared to other therapies. The primary efficacy analysis showed 68% of the intention to treat population (n=132) experienced at least a 50% reduction in urgency urinary incontinence episodes at 48 weeks post-activation; 16% of implanted subjects experienced device-related events through 52 weeks post-implantation. Author noted limitations included the lack of blinding and comparison along with the short term follow-up. The authors concluded that eCoin demonstrated clinical benefit for treating overactive bladder syndrome with automatic delivery of an intermittent low-duty cycle and implanted with a minimally invasive, brief procedure. Additional long term randomized control trials with large patient populations are needed to validate the outcomes of the study. No health disparities were identified by the investigators.

### **Professional Societies/Organizations**

**American Society of Colon and Rectal Surgeons (ASCRS):** The ASCRS issued a clinical practice guideline for the treatment of fecal incontinence which stated that percutaneous tibial nerve stimulation may be considered because it provides short-term improvement in episodes of fecal incontinence. Grade of Recommendation: Weak recommendation based on low- or very low-quality evidence (Paquette, et al., 2015).

**American Urological Association (AUA)/Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU):** The AUA/SUFU guideline on the diagnosis and treatment of non-neurogenic OAB in adults addressed using PTNS as a treatment option. The guideline stated that clinicians may offer PTNS as third-line treatment in a carefully selected patient population, characterized by moderately severe baseline incontinence and frequency and willingness to comply with the PTNS protocol. Additionally, the guidelines stated that patients must also have the resources to make frequent office visits both during the initial treatment phase and to obtain maintenance treatments in order to achieve and maintain treatment effects. This determination was based on evidence the AUA categorized as Grade C because of the primarily observational designs, varying patient inclusion criteria and short follow-up in most studies (Gormley, et al., 2012; Updated 2019).

### Use Outside of the US

The European Association of Urology published a guideline in 2018 on urinary incontinence in adults. They recommend offering SNS and PTNS as an option for improvement of urgency urinary incontinence in women who have not benefitted from antimuscarinic medication (Burkhard et al., 2018).

According to the National Institute for Clinical Excellence (NICE) guideline on the use of PTNS for overactive bladder syndrome, the current evidence shows that PTNS is efficacious in reducing symptoms in the short and medium term. There are no major safety concerns. Therefore the procedure may be used provided that normal arrangements are in place for clinical governance, consent and audit. It was noted that long-term efficacy has not been established (NICE, 2010). In their guidance on urinary incontinence and pelvic organ prolapse in women, NICE recommended only offering percutaneous posterior tibial nerve stimulation to women after a local multidisciplinary teams (MDT) review, non-surgical management has not been effective and the patient doesn't want botulinum toxin type A or percutaneous sacral nerve stimulation (NICE 2019).

In a 2011 interventional procedure guidance (IPG), NICE reported that percutaneous PTNS for fecal incontinence raised no safety concerns, but the procedure should only be used with special arrangements for clinical governance, consent and audit or research due to the limited number of studies with small patient populations and short-term data. Evidence was in the form of case series (n=22) and a non-randomized comparative study with 52 patients. Results of the therapy were "fair to good" but 30% of patients had a recurrence of symptoms by mean follow-up of 22.3 months. The published studies included patients with a variety of different conditions and not all patients had serious disability as a result of their symptoms.

## Medicare Coverage Determinations

	Contractor	Determination Name/Number	Revision Effective Date
NCD	National	Sacral Nerve Stimulation For Urinary Incontinence (230.18)	1/01/2012
LCD	National Government Services, Inc.	Posterior Tibial Nerve Stimulation for Voiding Dysfunction (L33396)	10/24/2019
LCD	First Coast Service Options, Inc.	Posterior Tibial Nerve Stimulation (PTNS) (L33406)	1/08/2019
LCD	Palmetto GBA	Posterior Tibial Nerve Stimulation (PTNS) for Urinary Control (L33443)	10/24/2019
LCD	Novitas Solutions, Inc.	Surgery: Posterior Tibial Nerve Stimulation (PTNS) for Urinary Control (L35011)	11/14/2019
NCD	National	Sacral Nerve Stimulation For Urinary Incontinence (230.18)	1/01/2012

Note: Please review the current Medicare Policy for the most up-to-date information. (NCD = National Coverage Determination; LCD = Local Coverage Determination.)

## Coding Information

**Note:** 1) This list of codes may not be all-inclusive.

2) Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement.

### **Sacral Nerve Stimulation (SNS)**

**Considered Medically Necessary as a screening trial for sacral nerve stimulation (SNS) when criteria in the applicable policy statements listed above are met:**

<b>CPT®* Codes</b>	<b>Description</b>
64561	Percutaneous implantation of neurostimulator electrode array; sacral nerve (transforaminal placement) including image guidance, if performed
64581	Open implantation of neurostimulator electrode array; sacral nerve (transforaminal placement)

<b>HCPCS Codes</b>	<b>Description</b>
C1778	Lead, neurostimulator (implantable)
C1897	Lead, neurostimulator test kit (implantable)

**Considered Medically Necessary for permanent SNS implantation when criteria in the applicable policy statements listed above are met:**

<b>CPT®* Codes</b>	<b>Description</b>
64581	Open implantation of neurostimulator electrode array; sacral nerve (transforaminal placement)
64585	Revision or removal of peripheral neurostimulator electrode array
64590	Insertion or replacement of peripheral or gastric neurostimulator pulse generator or receiver, direct or inductive coupling
64595	Revision or removal of peripheral or gastric neurostimulator pulse generator or receiver

<b>HCPCS Codes</b>	<b>Description</b>
A4290	Sacral nerve stimulation test lead, each
C1767	Generator, neurostimulator (implantable), non-rechargeable
C1778	Lead, neurostimulator (implantable)
C1787	Patient programmer, neurostimulator
C1820	Generator, neurostimulator (implantable), with rechargeable battery and charging system
C1883	Adaptor/extension, pacing lead or neurostimulator lead (implantable)
L8679	Implantable neurostimulator, pulse generator, any type
L8680	Implantable neurostimulator electrode, each
L8681	Patient programmer (external) for use with implantable programmable neurostimulator pulse generator, replacement only
L8682	Implantable neurostimulator radiofrequency receiver
L8685	Implantable neurostimulator pulse generator, single array, rechargeable, includes extension
L8686	Implantable neurostimulator pulse generator, single array, non-rechargeable, includes extension
L8687	Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension
L8688	Implantable neurostimulator pulse generator, dual array, non-rechargeable, includes extension

### **Percutaneous Tibial Nerve Stimulation (PTNS)**

**Considered Medically Necessary when used to report PTNS treatment of overactive bladder symptoms when criteria in the applicable policy statements listed above are met:**

<b>CPT®* Codes</b>	<b>Description</b>
64566	Posterior tibial neurostimulation, percutaneous needle electrode, single treatment, includes programming

**Considered Experimental/Investigational/Unproven when used to report PTNS for fecal incontinence and constipation:**

<b>CPT®* Codes</b>	<b>Description</b>
64566	Posterior tibial neurostimulation, percutaneous needle electrode, single treatment, includes programming

**Considered Experimental/Investigational/Unproven when used to report Implantable tibial nerve stimulation for the treatment of urinary voiding dysfunction (e.g., overactive bladder, urinary urge incontinence), fecal incontinence and constipation:**

<b>CPT®* Codes</b>	<b>Description</b>
0587T	Percutaneous implantation or replacement of integrated single device neurostimulation system including electrode array and receiver or pulse generator, including analysis, programming, and imaging guidance when performed, posterior tibial nerve
0588T	Revision or removal of integrated single device neurostimulation system including electrode array and receiver or pulse generator, including analysis, programming, and imaging guidance when performed, posterior tibial nerve
0589T	Electronic analysis with simple programming of implanted integrated neurostimulation system (eg, electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, posterior tibial nerve, 1-3 parameters
0590T	Electronic analysis with complex programming of implanted integrated neurostimulation system (eg, electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, posterior tibial nerve, 4 or more parameters

**\*Current Procedural Terminology (CPT®) ©2021 American Medical Association: Chicago, IL.**

## References

1. Abello A, Das AK. Electrical neuromodulation in the management of lower urinary tract dysfunction: evidence, experience and future prospects. *Ther Adv Urol.* 2018 Feb 22;10(5):165-173.
2. Abrams P, Andersson KE, Apostolidis A., Birder L, Bliss D, Brubaker L, et al. Sixth international consultation on incontinence. Recommendations of the International Scientific Committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse, and faecal incontinence. *Neurourol Urodyn.* 2018 Sep;37(7):2271-2272.
3. American College of Obstetricians and Gynecologists (ACOG). Committee on Practice Bulletins—Gynecology and the American Urogynecologic Society. ACOG Practice Bulletin. Clinical management

guidelines for obstetrician-gynecologists. Number 155. Urinary incontinence in women. *Obstet Gynecol*. 2015 Nov;126(5):e66-81. Reaffirmed 2022.

4. Balk E, Adam GP, Kimmel H, Rofeberg V, Saeed I, Jeppson P, et al. Nonsurgical Treatments for Urinary Incontinence in Women: A Systematic Review Update. *Comparative Effectiveness Review No. 212*. (Prepared by the Brown Evidence-based Practice Center under Contract No. 290-2015-00002-I for AHRQ and PCORI.) AHRQ Publication No. 18-EHC016-EF. PCORI Publication No. 2018-SR-03. Rockville, MD: Agency for Healthcare Research and Quality; August 2018.
5. Barker A, Hurley J. Novel treatment options for fecal incontinence. *Clin Colon Rectal Surg*. 2014 Sep;27(3):116-20.
6. Benezech A, Bouvier M, Vitton V. Faecal incontinence: Current knowledges and perspectives. *World J Gastrointest Pathophysiol*. 2016 Feb 15;7(1):59-71.
7. Bharucha AE, Dorn SD, Lembo A, Pressman A. American Gastroenterological Association medical position statement on constipation. *Gastroenterology*. 2013 Jan;144(1):211-7.
8. Bharucha AE, Rao SSC, Shin AS. Surgical Interventions and the Use of Device-Aided Therapy for the Treatment of Fecal Incontinence and Defecatory Disorders. *Clin Gastroenterol Hepatol*. 2017 Dec;15(12):1844-1854.
9. Biemans JM, van Balken MR. Efficacy and effectiveness of percutaneous tibial nerve stimulation in the treatment of pelvic organ disorders: a systematic review. *Neuromodulation*. 2013 Jan-Feb;16(1):25-33; discussion 33.
10. Blue Cross Blue Shield Association Technology Evaluation Center (TEC). *Percutaneous Tibial Nerve Stimulation for the Treatment of Voiding Dysfunction*. Volume 28, No. 10 January 2014. © 2014 Blue Cross and Blue Shield Association.
11. Boyle DJ, Murphy J, Gooneratne ML, Grimmer K, Allison ME, Chan CL, et al. Efficacy of sacral nerve stimulation for the treatment of fecal incontinence. *Dis Colon Rectum*. 2011 Oct;54(10):1271-8.
12. Burkhard FC, Bosch JLHR, Cruz F, Lemack GE, Nambiar AK, Thiruchelvam N, et al. *European Association of Urology Guidelines 2018 Edition. Urinary Incontinence in Adults*. 2018. Accessed July 28, 2022. Available at URL address: <http://uroweb.org/guideline/urinary-incontinence/>
13. Burton C, Sajja A, Latthe PM. Effectiveness of percutaneous posterior tibial nerve stimulation for overactive bladder: A systematic review and meta-analysis. *Neurourol Urodyn*. 2012 Nov;31(8):1206-16.
14. Centers for Medicare and Medicaid Services (CMS). *Local Coverage Determinations (LCDs) alphabetical index*. Accessed July 28, 2022. Available at URL address: <https://www.cms.gov/medicare-coverage-database/indexes/lcd-alphabetical-index.aspx>
15. Centers for Medicare and Medicaid Services (CMS). *National Coverage Determinations (NCDs) alphabetical index*. Accessed July 28, 2022. Available at URL address: <https://www.cms.gov/medicare-coverage-database/indexes/ncd-alphabetical-index.aspx>
16. Chan M, Tjandra JJ. Sacral nerve stimulation for fecal incontinence: external anal sphincter defect vs intact anal sphincter. *Dis Colon Rectum*. 2008 Jul;51(7): 1015-1025.
17. Cogentix Medical. *Urgent® PC Neuromodulation System*. ©2022 Cogentix Medical. Accessed on July 28, 2022. Available at URL address: <http://www.uroplasty.com/healthcare/urgentpc>

18. Damon H, Barth X, Roman S, Mion F. Sacral nerve stimulation for fecal incontinence improves symptoms, quality of life and patients' satisfaction: results of a monocentric series of 119 patients. *Int J Colorectal Dis.* 2013 Feb;28(2):227-33.
19. Deng Y, Dong Y, Liu Y, Zhang Q, Guan X, Chen X, et al. A systematic review of clinical studies on electrical stimulation therapy for patients with neurogenic bowel dysfunction after spinal cord injury. *Medicine (Baltimore).* 2018 Oct;97(41):e12778.
20. Devroede G, Giese C, Wexner SD, Mellgren A, Collier JA, Madoff RD, et al. Quality of life is markedly improved in patients with fecal incontinence after sacral nerve stimulation. *Female Pelvic Med Reconstr Surg.* 2012 Mar-Apr;18(2):103-12.
21. Dorsthorst MJT, Digesu GA, Tailor V, Gore M, van Kerrebroeck PE, van Breda HMK, et al. 3-Year Followup of a New Implantable Tibial Nerve Stimulator for the Treatment of Overactive Bladder Syndrome. *J Urol.* 2020 Sep;204(3):545-550.
22. Edenfield AL, Amundsen CL, Wu JM, et al. Posterior tibial nerve stimulation for the treatment of fecal incontinence: A systematic evidence review. *Obstet Gynecol Surv.* 2015;70(5):329-341.
23. Everaert K, Kerckhaert W, Caluwaerts H, Audenaert M, Vereecke H, De Cuypere G, et al. A prospective randomized trial comparing the 1 stage with the 2 stage implantation of a pulse generator in patients with pelvic floor dysfunction selected for sacral nerve stimulation. *Eur Urol.* 2004 May;45(5):649-54.
24. Fargo MV, Latimer KM. Evaluation and management of common anorectal conditions. *Am Fam Physician.* 2012 Mar 15;85(6):624-30.
25. Finazzi-Agrò E, Petta F, Sciobica F, Pasqualetti P, Musco S, Bove P. Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo controlled trial. *J Urol.* 2010 Nov;184(5):2001-6.
26. Forte ML, Andrade KE, Butler M, Lowry AC, Bliss DZ, Slavin JL, Kane RL. Treatments for Fecal Incontinence. Comparative Effectiveness Review No. 165. (Prepared by the Minnesota Evidence-based Practice Center under Contract No. 290-2012-00016-I.) AHRQ Publication No. 15(16)-EHC037-EF. Rockville, MD: Agency for Healthcare Research and Quality; March 2016. Accessed July 28, 2022. Available at URL address: <https://effectivehealthcare.ahrq.gov/topics/fecal-incontinence/research>
27. Gaziev G, Topazio L, Iacovelli V, Asimakopoulos A, Di Santo A, De Nunzio C, et al. Percutaneous Tibial Nerve Stimulation (PTNS) efficacy in the treatment of lower urinary tract dysfunctions: a systematic review. *BMC Urol.* 2013 Nov 25;13:61.
28. George AT, Maitra RK, Maxwell-Armstrong C. Posterior tibial nerve stimulation for fecal incontinence: Where are we? *World J Gastroenterol.* 2013 December 28; 19(48): 9139–45.
29. George AT, Kalmar K, Sala S, Kopanakis K, Panarese A, Dudding TC, Hollingshead JR, Nicholls RJ, Vaizey CJ. Randomized controlled trial of percutaneous versus transcutaneous posterior tibial nerve stimulation in faecal incontinence. *Br J Surg.* 2013 Feb;100(3):330-8.
30. Gladman MA, Knowles CH. Surgical treatment of patients with constipation and fecal incontinence. *Gastroenterol Clin North Am.* 2008 Sep;37(3):605-25, viii.
31. Gilling P, Meffan P, Kaaki B, MacDiarmid S, Lucente V, Clark M, et al. Twelve-month Durability of a Fully-implanted, Nickel-sized and Shaped Tibial Nerve Stimulator for the Treatment of Overactive Bladder Syndrome with Urgency Urinary Incontinence: A Single-Arm, Prospective Study. *Urology.* 2021 Nov;157:71-78.



32. Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, et al. Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline. Published 2012; Amended 2014, 2019. Accessed July 28, 2022. Available at URL address: [https://www.auanet.org/guidelines/overactive-bladder-\(oab\)-guideline](https://www.auanet.org/guidelines/overactive-bladder-(oab)-guideline)
33. Gungor Ugurlucan F, Onal M, Aslan E, Ayyildiz Erkan H, Kizilkaya Beji N, Yalcin O. Comparison of the effects of electrical stimulation and posterior tibial nerve stimulation in the treatment of overactive bladder syndrome. *Gynecol Obstet Invest.* 2013;75(1):46-52.
34. Hassouna M, Siegel S, Lycklama A. Sacral Nerve Stimulation Study Group. Sacral neuromodulation in the treatment of urgency-frequency symptoms: a multicenter study on efficacy and safety. *J Urol.* 2000;163:1849-1854.
35. Hassouna M, Alabbad A. Sacral Nerve Neuromodulation. In: Krames ES, Peckham PH, Rezai AR. *Neuromodulation; Comprehensive Textbook of Principles, Technologies, and Therapies.* 2nd ed. St. Louis, MO: Elsevier Ltd; 2018. Ch 122. pgs 1451-1454.
36. Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, Monga A, Petri E, Rizk DE, Sand PK, Schaer GN; International Urogynecological Association; International Continence Society. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. *Neurourol Urodyn.* 2010;29(1):4-20.
37. Hayes, Inc. Medical Technology Directory Report. Staged Approach to Sacral Nerve Stimulation for Treatment of Fecal Incontinence. Hayes, Inc.; published Dec, 2015.
38. Hayes Inc. Medical Technology Directory Report. Percutaneous Tibial Nerve Stimulation for the Treatment of Symptomatic Neurogenic Lower Urinary Tract Dysfunction. Hayes, Inc.; published April 2019.
39. Heesakkers J, Digesu GA, van Breda J, Van Kerrebroeck P, Elneil S. A novel leadless, miniature implantable tibial nerve neuromodulation system for the management of overactive bladder complaints. *Neurourol Urodyn* 2018;37(3):1060–1067.
40. Herbison GP, Arnold EP. Sacral neuromodulation with implanted devices for urinary storage and voiding dysfunction in adults. *Cochrane Database Sys Rev.* 2009 Apr 15;(2):CD004202.
41. Horrocks EJ, Thin N, Thaha MA, Taylor SJ, Norton C, Knowles CH. Systematic review of tibial nerve stimulation to treat faecal incontinence. *Br J Surg.* 2014 Apr;101(5):457-68.
42. Hull T, Giese C, Wexner SD, Mellgren A, Devroede G, Madoff RD, et al. Long-term durability of sacral nerve stimulation therapy for chronic fecal incontinence. *Dis Colon Rectum.* 2013 Feb;56(2):234-45.
43. Jarrett MED, Mowatt G, Glazener CM, Fraser C, Nicholls RJ, Grant AM, et al. Systematic review of sacral nerve stimulation for faecal incontinence and constipation. *Br J Surg.* 2004 Dec;91(12):1559-69.
44. Kaaki B, English S, Gilling P, Meffan P, Lucente V, MacDiarmid S, et al. Six-Month Outcomes of Reimplantation of a Coin-Sized Tibial Nerve Stimulator for the Treatment of Overactive Bladder Syndrome With Urgency Urinary Incontinence. *Female Pelvic Med Reconstr Surg.* 2022 May 1;28(5):287-292
45. Kirby AC, Lentz GM. Lower Urinary Tract Function and Disorders: Physiology of Micturition, Voiding Dysfunction, Urinary Incontinence, Urinary Tract Infections, and Painful Bladder Syndrome. In: Lobo RA; Gershenson DM; Lentz GM; Valea FA. *Comprehensive Gynecology.* 7th Edition. St. Louis, MO: Elsevier Ltd; 2017. Ch 21. Pgs 474-504.
46. Knowles CH, Horrocks EJ, Bremner SA, Stevens N, Norton C, O'Connell PR5, Eldridge S; CONFIDeNT study group. Percutaneous tibial nerve stimulation versus sham electrical stimulation for the treatment of

faecal incontinence in adults (CONFIDeNT): a double-blind, multicentre, pragmatic, parallel-group, randomised controlled trial. *Lancet*. 2015 Oct 24;386(10004):1640-8.

47. Kumar L, Liwanag J, Athanasakos E, Raeburn A, Zarate-Lopez N, Emmanuel AV. Effectiveness of percutaneous tibial nerve stimulation in managing refractory constipation. *Colorectal Dis*. 2016 May 20.
48. Lashin AM, Eltabey NA, Wadie BS. Percutaneous tibial nerve stimulation versus sham efficacy in the treatment of refractory overactive bladder: outcomes following a shortened 6-week protocol, a prospective randomized controlled trial. *Int Urol Nephrol*. 2021 Dec;53(12):2459-2467.
49. Leroi AM, Parc Y, Lehur PA, Mion F, Barth X, Rullier E, et al. Efficacy of sacral nerve stimulation for fecal incontinence: results of a multicenter double-blind crossover study. *Ann Surg*. 2005 Nov;242(5):662-9.
50. Levin PJ, Wu JM, Kawasaki A, Weidner AC, Amundsen CL. The efficacy of posterior tibial nerve stimulation for the treatment of overactive bladder in women: a systematic review. *Int Urogynecol J*. 2012 Nov;23(11):1591-7.
51. Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment 2019. *J Urol*. 2019;202(3):558-563.
52. MacDiarmid SA, Peters KM, Shobeiri SA, Wooldridge LS, Rovner ES, Leong FC, et al. Long-term durability of percutaneous tibial nerve stimulation for the treatment of overactive bladder. *J Urol*. 2010 Jan;183(1):234-40. *J Urol*. 2010 Apr;183(4):1438-43.
53. Maeda Y, Kamm MA, Vaizey CJ, Matzel KE, Johansson C, Rosen H, et al. Long-term outcome of sacral neuromodulation for chronic refractory constipation. *Tech Coloproctol* 2017 Apr;21(4):277-286.
54. Manso B, Alias D, Franco R, Levano-Linares C, Laiz B, Garcia-Olmo D, Duran M, Ruiz-Tovar J. Percutaneous electrical stimulation of the posterior tibial nerve for the treatment of fecal incontinence: manometric results after 6 months of treatment. *Int J Colorectal Dis*. 2020 Jul 5.
55. Marinello FG, Jiménez LM, Talavera E, Fracalvieri D, Alberti P, Ostiz F, et al. Percutaneous tibial nerve stimulation in patients with severe low anterior resection syndrome: randomized clinical trial. *Br J Surg*. 2021 Apr 30;108(4):380-387.
56. Martin-Garcia M, Crampton J. A single-blind, randomized controlled trial to evaluate the effectiveness of transcutaneous tibial nerve stimulation (TTNS) in Overactive Bladder symptoms in women responders to percutaneous tibial nerve stimulation (PTNS). *Physiotherapy*. 2018 Dec 18. pii: S0031-9406(18)30650-3.
57. Matzel KE. Sacral nerve stimulation for faecal incontinence: its role in the treatment algorithm. *Colorectal Dis*. 2011 Mar;13 Suppl 2:10-4.
58. Matzel KE, Lux P, Heuerr S, Besendorf er M, Zhang W. Sacral nerve stimulation for faecal incontinence: long-term outcome. *Colorectal Dis*. 2009 Jul;11(6):636-41.
59. Medtronic, Inc. Indications, Safety, and Warnings Sacral Neuromodulation. ©2022 Medtronic, Inc. Updated October 2019. Accessed July 28, 2022. Available at URL address: <https://www.medtronic.com/us-en/healthcare-professionals/products/urology/sacral-neuromodulation-systems/interstim-ii/indications-safety-warnings.html>
60. Medtronic, Inc. Medtronic receives FDA approval for InterStim X™ system, the next generation of the most personalized sacral nerve stimulation therapy for bladder and bowel control. ©2022 Medtronic, Inc. February 22, 2022. Accessed July 28, 2022. Available at URL address: <https://news.medtronic.com/2022-02-22-Medtronic-receives-FDA-approval-for-InterStim-X-TM-system,-the-next-generation-of-the-most-personalized-sacral-nerve-stimulation-therapy-for-bladder-and-bowel-control>

61. Melenhorst J, Koch SM, Uludag O, van Gemert WG, Baeten CG. Sacral neuromodulation in patients with faecal incontinence: results of the first 100 permanent implantations. *Colorectal Dis.* 2007 Oct;9(8):725-30.
62. Mellgren A. Fecal incontinence. *Surg Clin North Am.* 2010 Feb;90(1):185-94, Table of Contents.
63. Mellgren A, Wexner SD, Collier JA, Devroede G, Lerew DR, Madoff RD, et al. Long-term efficacy and safety of sacral nerve stimulation for fecal incontinence. *Dis Colon Rectum.* 2011 Sep;54(9):1065-1075.
64. Meurette G, La Torre M, Regenet N, Robert-Yap J, Lehur PA. Value of sacral nerve stimulation in the treatment of severe faecal incontinence: a comparison to the artificial bowel sphincter. *Colorectal Dis.* 2009 Jul;11(6):631-5.
65. Michelson HB, Thompson-Fawcett M, Lundby M, Krogh K, Laurberg s, Buntzen S. Six years of experience with sacral nerve stimulation for fecal incontinence. *Dis Colon Rectum.* 2010 Apr;53(4):414-21.
66. Monga AK, Tracey MR, Subbaroyan J. A systematic review of clinical studies of electrical stimulation for treatment of lower urinary tract dysfunction. *Int Urogynecol J.* 2012 Aug;23(8):993-1005.
67. Moore CK, Rueb JJ, et al. What Is New in Neuromodulation? *Curr Urol Rep.* 2019 Aug 7;20(9):55.
68. Moossdorff-Steinhauser HF, Berghmans B. Effects of percutaneous tibial nerve stimulation on adult patients with overactive bladder syndrome: a systematic review. *Neurourol Urodyn.* 2013 Mar;32(3):206- 14.
69. Mowatt G, Glazener C, Jarrett M. Sacral nerve stimulation for fecal incontinence and constipation in adults: a short version Cochrane review. *Neurourol Urodyn.* 2008;27(3):155-61.
70. Moya P, Parra P, Arroyo A, Peña E, Benavides J, Calpena R. Sacral nerve stimulation versus percutaneous posterior tibial nerve stimulation in the treatment of severe fecal incontinence in men. *Tech Coloproctol* 2016 May;20(5):317-319.
71. National Institute for Clinical Excellence (NICE). Faecal incontinence in adults: management. June 2007; updated 2018. Accessed July 28, 2022. Available at URL address: <https://www.nice.org.uk/guidance/cg49>
72. National Institute for Health and Clinical Excellence (NICE). IPG 395. Percutaneous tibial nerve stimulation for faecal incontinence May 2011. Accessed July 28, 2022. Available at URL address: <https://www.nice.org.uk/guidance/ipg395>
73. National Institute for Clinical Excellence (NICE). Percutaneous posterior tibial nerve stimulation for overactive bladder syndrome. October 2010. Accessed July 28, 2022. Available at URL address: <https://www.nice.org.uk/guidance/ipg362>
74. National Institute for Clinical Excellence (NICE). Sacral nerve stimulation for faecal incontinence. November 2004a. Update 2012. Accessed July 28, 2022. Available at URL address: <https://www.nice.org.uk/guidance/ipg99>
75. National Institute for Clinical Excellence (NICE). Sacral nerve stimulation for urge incontinence and urgency-frequency. June 2004b. Update 2012. Accessed August July 28, 2022. Available at URL address: <https://www.nice.org.uk/guidance/ipg64>
76. National Institute for Clinical Excellence (NICE). Sacral nerve stimulation for idiopathic chronic non-obstructive urinary retention. November 2015. Accessed July 28, 2022. Available at URL address: <https://www.nice.org.uk/guidance/ipg536>
77. National Institute for Clinical Excellence (NICE). Urinary incontinence and pelvic organ prolapse in women: management. April 2019, updated June 2019. Accessed July 28, 2022. Available at URL address: <https://www.nice.org.uk/guidance/ng123>

78. Noblett K, Siegel S, Mangel J, Griebing TL, Sutherland SE, Bird ET, et al. Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder. *Neurourol Urodyn*. 2014 Dec 24.
79. Paquette IM, Varma MG, Kaiser AM, Steele SR, Rafferty JF. The American Society of Colon and Rectal Surgeons' Clinical Practice Guideline for the Treatment of Fecal Incontinence. *Dis Colon Rectum*. 2015 Jul;58(7):623-36.
80. Paquette IM, Varma M, Ternent C, Melton-Meaux G, Rafferty JF, Feingold D, et al. The American Society of Colon and Rectal Surgeons' Clinical Practice Guideline for the Evaluation and Management of Constipation. *Dis Colon Rectum*. 2016 Jun;59(6):479-92.
81. Peña Ros E, Parra Baños PA, Benavides Buleje JA, Muñoz Camarena JM, Escamilla Segade C, Candel Arenas MF, Gonzalez Valverde FM, Albarracín Marín-Blázquez A. Short-term outcome of percutaneous posterior tibial nerve stimulation (PTNS) for the treatment of faecal incontinence. *Tech Coloproctol*. 2016 Jan;20(1):19-24.
82. Peters KM, Carrico DJ, Perez-Marrero RA, Khan AU, Wooldridge LS, Davis GL, et al. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmIT trial. *J Urol*. 2010 Apr;183(4):1438-43.
83. Peters KM, Carrico DJ, Wooldridge LS, Miller CJ, MacDiarmid SA. Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study. *J Urol*. 2013 Jun;189(6):2194-201.
84. Peters KM, Macdiarmid SA, Wooldridge LS, Leong FC, Shobeiri SA, Rovner ES, et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. *J Urol*. 2009 Sep;182(3):1055-61
85. Pilkington SA, Emmett C, Knowles CH, Mason J, Yiannakou Y; NIHR CapaCITY working group; Pelvic floor Society. Surgery for constipation: systematic review and practice recommendations: Results V: Sacral Nerve Stimulation. *Colorectal Dis*. 2017 Sep;19
86. Rodríguez Carrillo R, Ruiz Carmona MD, Alós Company R, Frangi Caregnato A, Alarcón Iranzo M, Solana Bueno A, Lozoya Trujillo R, García-Granero Ximénez E. Evaluation of the anorectal motor response after percutaneous stimulation of the posterior tibial nerve in patients with fecal incontinence. *Tech Coloproctol*. 2019 Oct;23(10):987-992.
87. Rogers A, Bragg S, Ferrante K, Thenuwara C, Peterson DKL. Pivotal Study of Leadless Tibial Nerve Stimulation with eCoin® for Urgency Urinary Incontinence: An Open-Label, Single Arm Trial. *J Urol*. 2021 Aug;206(2):399-408.
88. Rydningen M, Dehli T, Wilsgaard T, Rydning A, Kumle M, Lindsetmo RO, et al. Sacral neuromodulation compared with injection of bulking agents for faecal incontinence following obstetric anal sphincter injury - a randomized controlled trial. *Colorectal Dis*. 2017 May;19(5):O134-O144.
89. Salatzki J, Liechti MD, Spanudakis E, Gonzales G, Baldwin J, Haslam C, Pakzad M, Panicker JN. Factors influencing return for maintenance treatment with percutaneous tibial nerve stimulation for the management of the overactive bladder. *BJU Int*. 2019 May;123(5A):E20-E28.
90. Scaldazza CV, Morosetti C, Giampieretti R, Lorenzetti R, Baroni M. Percutaneous tibial nerve stimulation versus electrical stimulation with pelvic floor muscle training for overactive bladder syndrome in women: results of a randomized controlled study. *Int Braz J Urol*. 2016 Nov 2.

91. Schmidt RA, Jonas U, Oleson KA, Janknegt RA, Hassouna MM, Siegel SW, et al. Sacral nerve stimulation for treatment of refractory urinary urge incontinence. Sacral Nerve Stimulation Study Group. *J Urol*. 1999 Aug;162(2):352-57.
92. Shamliyan T, Wyman J, Kane RL. Nonsurgical Treatments for Urinary Incontinence in Adult Women: Diagnosis and Comparative Effectiveness. Comparative Effectiveness Review No. 36. (Prepared by the University of Minnesota Evidence-based Practice Center under Contract No. HHS 290-2007-10064-I.) AHRQ Publication No. 11(12)-EHC074-EF. Rockville, MD. Agency for Healthcare Research and Quality. April 2012. Accessed July 28, 2022. Available at URL address: <https://effectivehealthcare.ahrq.gov/products/urinary-incontinence-treatment/research>
93. Shamliyan T, Wyman J, Bliss DZ, Kane RL, Wilt TJ. Prevention of urinary and fecal incontinence in adults. Evidence Report/Technology Assessment No. 161. (Prepared by the University of Minnesota Evidence-based Practice Center under Contract No. Contract No. 290-02-0009) AHRQ Publication No. 08-E003. Rockville, MD. Agency for Healthcare Research and Quality. December 2007.
94. Siegel S, Noblett K, Mangel J, Griebing TL, Sutherland SE, Bird ET, et al. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder. *Neurourol Urodyn*. 2015 Mar;34(3):224-30.
95. Simillis C, Lal N, Pellino G, Baird D, Nikolaou S, Kontovounisios C, et al. A systematic review and network meta-analysis comparing treatments for faecal incontinence. *Int J Surg*. 2019 Jun;66:37-47.
96. Simillis C, Lal N, Qiu S, Kontovounisios C, Rasheed S, Tan E, et al. Sacral nerve stimulation versus percutaneous tibial nerve stimulation for faecal incontinence: a systematic review and meta-analysis. *Int J Colorectal Dis*. 2018 May;33(5):645-648.
97. Solon JG, Waudby P, O'Grady H. Percutaneous tibial nerve stimulation can improve symptoms and quality of life in selected patients with faecal incontinence - A single-centre 5-year clinical experience. *Surgeon*. 2020 Jun;18(3):154-158.
98. Sonmez R, Yildiz N, Alkan H. Efficacy of percutaneous and transcutaneous tibial nerve stimulation in women with idiopathic overactive bladder: A prospective randomised controlled trial. *Ann Phys Rehabil Med*. 2022 Jan;65(1):101486.
99. Sutherland SE, Lavers A, Carlson A, Holtz C, Keshava J, Siegel SW. Sacral nerve stimulation for voiding dysfunction: One institution's 11-year experience. *Neurourol Urodyn*. 2007;26(1):19-28; discussion 36.
100. Syan R, Zhang CA, Enemchukwu EA. Racial and Socioeconomic Factors Influence Utilization of Advanced Therapies in Commercially Insured OAB Patients: An Analysis of Over 800,000 OAB Patients. *Urology*. 2020 Aug;142:81-86.
101. Szymański JK, Słabuszewska-Józwiak A, Zaręba K, Jakiel G. Neuromodulation - a therapeutic option for refractory overactive bladder. A recent literature review. *Wideochir Inne Tech Maloinwazyjne*. 2019 Dec;14(4):476-485.
102. Tan E, Ngo NT, Darzi A, Shenouda M, Tekkis PP. Meta-analysis: sacral nerve stimulation versus conservative therapy in the treatment of faecal incontinence. *Int J Colorectal Dis*. 2011 Mar;26(3):275-94.
103. Thaha MA, Abukar AA, Thin NN, Ramsanahie A, Knowles CH. Sacral nerve stimulation for faecal incontinence and constipation in adults. *Cochrane Database Syst Rev*. 2015 Aug 24;(8):CD004464.
104. Thin NN, Horrocks EJ, Hotouras A, Palit S, Thaha MA, Chan CL, Matzel KE, Knowles CH. Systematic review of the clinical effectiveness of neuromodulation in the treatment of faecal incontinence. *Br J Surg*. 2013 Oct;100(11):

105. Tjandra JJ, Chan MKY, Yeh CH, Murray-Green C. Sacral nerve stimulation is more effective than optimal medical therapy for severe fecal incontinence: a randomized, controlled study. *Dis Colon Rectum*. 2008 May;51(5):494-502.
106. Tutolo M, Ammirati E, Heesakkers J, Kessler TM, Peters KM, Rashid T, Sievert KD, et al. Efficacy and safety of sacral and percutaneous tibial neuromodulation in non-neurogenic lower urinary tract dysfunction and chronic pelvic pain: a systematic review of the literature. *Eur Urol* 2018 Jan 11.
107. Uludag O, Mellenhorst J, Koch M, van Gemert WG, Dejong CHC, Baeten CG, Sacral neuromodulation: long-term outcome and quality of life in patients with faecal incontinence. *Dis Colon Rectum*, 2011 Oct; 13(10):1162-6.
108. United States Food and Drug Administration (FDA). PMA database. P180046. Axonics Sacral Neuromodulation System. 2019a November. Accessed July 28, 2022. Available at URL address: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P080025>
109. United States Food and Drug Administration (FDA). PMA database. P190006. Axonics Sacral Neuromodulation System. 2019b November. Accessed July 28, 2022. Available at URL address: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P190006>
110. United States Food and Drug Administration (FDA). PMA database. P200036. ECoin® Peripheral Neurostimulator. 2022 July. Accessed August 18, 2022. Available at URL address: <https://www.accessdata.fda.gov/SCRIPTS/cdrh/devicesatfda/index.cfm?db=pma&id=504879>
111. United States Food and Drug Administration (FDA). PMA database. P080025. Medtronic™ Interstim™ Sacral Nerve Stimulation Therapy System. 2011 March. Accessed July 28, 2022. Available at URL address: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P080025>
112. United States Food and Drug Administration (FDA). PMA database. P080025/S197. InterStim Micro System. 2020 July. Accessed July 28, 2022. Available at URL address: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P080025S197>
113. United States Food and Drug Administration (FDA). PMA database. P970004. Medtronic™ Interstim™ System for Urinary Control. 1997 September. Accessed July 28, 2022. Available at URL address: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P970004>
114. United States Food and Drug Administration (FDA). PMA database. P970004/S004. Medtronic™ Interstim™ System for Urinary Control. 1999 April. Accessed July 28, 2022. Available at URL address: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P970004S004>
115. United States Food and Drug Administration (FDA). PMA database. P970004/S013. Medtronic™ Interstim™ System for Urinary Control. 2001 April. Accessed July 28, 2022. Available at URL address: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P970004S013>
116. United States Food and Drug Administration (FDA). PMA database. P970004/S021. Medtronic™ Interstim™ System for Urinary Control. 2002 February. Accessed July 28, 2022. Available at URL address: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P970004S021>
117. United States Food and Drug Administration (FDA). PMA database. P970004/S302. Medtronic™ InterStim Micro System. 2020 July. Accessed July 28, 2022. Available at URL address: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P970004S302>
118. United States Food and Drug Administration (FDA). PMA database. P080025/S235. Medtronic™ InterStim X INS. 2022 February. Accessed July 28, 2022. Available at URL address: <https://www.accessdata.fda.gov/SCRIPTS/cdrh/devicesatfda/index.cfm?db=pma&id=490550>

119. United States Food and Drug Administration (FDA). PMA database. P970004/S340. Medtronic™ InterStim X INS. 2022 February. Accessed July 28, 2022. Available at URL address:  
<https://www.accessdata.fda.gov/SCRIPTS/cdrh/devicesatfda/index.cfm?db=pma&id=490548>
120. United States Food and Drug Administration (FDA). 510(k) summary. Center for Devices and Radiological Health (CDRH). K132561. NURO Neuromodulation System. November 2013. Accessed July 28, 2022. Available at URL address:  
<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmnmn.cfm?ID=K132561>
121. United States Food and Drug Administration (FDA). 510(k) summary. Center for Devices and Radiological Health (CDRH). K052025. Urgent® PC Neuromodulation System. October 2005. Accessed July 28, 2022. Available at URL address:  
<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmnmn.cfm?ID=K052025>
122. United States Food and Drug Administration (FDA). 510(k) summary. Center for Devices and Radiological Health (CDRH). K101847. Urgent® PC Neuromodulation System. October 2010. Accessed July 28, 2022. Available at URL address:  
<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmnmn.cfm?ID=K101847>
123. van Breda HMK, Martens FMJ, Tromp J, Heesakkers J. A new implanted posterior tibial nerve stimulator for the treatment of overactive bladder syndrome: 3-month results of a novel therapy at a single center. *J Urol* 2017;198(1):205–210.
124. Van der Pal F, van Balken MR, Heesakkers JP, Debruyne FM, Bemelmans BL. Percutaneous tibial nerve stimulation in the treatment of refractory overactive bladder syndrome: is maintenance treatment necessary? *BJU Int*. 2006 Mar; 97(3): 547-50.
125. van der Wilt AA, Giuliani G, Kubis C, van Wunnik BPW, Ferreira I, Breukink SO, et al. Randomized clinical trial of percutaneous tibial nerve stimulation versus sham electrical stimulation in patients with faecal incontinence. *Br J Surg*. 2017 Aug;104(9):1167-1176.
126. van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP, Lycklama a Nijholt AA, Siegel S, Jonas U, et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. *J Urol*. 2007 Nov;178(5):2029-34.
127. Vecchioli-Scaldazza C, Morosetti C, Berouz A, Giannubilo W, Ferrara V. Solifenacin succinate versus percutaneous tibial nerve stimulation in women with overactive bladder syndrome: results of a randomized controlled crossover study. *Gynecol Obstet Invest*. 2013;75(4):230-4.
128. Vecchioli-Scaldazza C, Morosetti C. Effectiveness and durability of solifenacin versus percutaneous tibial nerve stimulation versus their combination for the treatment of women with overactive bladder syndrome: a randomized controlled study with a follow-up of ten months. *Int Braz J Urol* 2018 Jan-Feb;44(1):102-108.
129. Wald A. Update on the Management of Fecal Incontinence for the Gastroenterologist. *Gastroenterol Hepatol (N Y)*. 2016 Mar;12(3):155-64.
130. Wald A, Bharucha AE, Limketkai B, Malcolm A, Remes-Troche JM, Whitehead WE, Zutshi M. ACG Clinical Guidelines: Management of Benign Anorectal Disorders. *Am J Gastroenterol*. 2021 Oct 1;116(10):1987-2008.
131. Wexner SD, Collier JA, Devroede G, Hull T, McCallum R, Chan M, et al. Sacral nerve stimulation for fecal incontinence: results of a 120-patient prospective multicenter study. *Ann Surg*. 2010 Mar;251(3):441-9.

132. Wexner SD, Hull T, Edden Y, Collier JA, Devroede G, McCallum R, et al. Infection rates in a large investigational trial of sacral nerve stimulation for fecal incontinence. *J Gastrointest. Surg.* 2010 Jul;14(7):1081-9.
133. White WM, Dobmeyer-Dittrich C, Klein FA, Wallace LS. Sacral nerve stimulation for treatment of refractory urinary retention: long-term efficacy and durability. *Urology.* 2008 Jan;71(1):71-4.
134. Whitehead WE, Rao SS, Lowry A, Nagle D, Varma M, Bitar KN, Bharucha AE, Hamilton FA. Treatment of fecal incontinence: state of the science summary for the National Institute of Diabetes and Digestive and Kidney Diseases workshop. *Am J Gastroenterol.* 2015 Jan;110(1):138-46.
135. Yamashiro J, de Riese W, de Riese C. New Implantable Tibial Nerve Stimulation Devices: Review of Published Clinical Results in Comparison to Established Neuromodulation Devices. *Res Rep Urol.* 2019 Dec 23;11:351-357.
136. Yoong W, Shah P, Dadswell R, Green L. Sustained effectiveness of percutaneous tibial nerve stimulation for overactive bladder syndrome: 2-year follow-up of positive responders *Int Urogynecol J.* 2013 May;24(5):795-9.
137. Zyczynski HM, Richter HE, Sung VW, Lukacz ES, Arya LA, Rahn DD, et al. Percutaneous Tibial Nerve Stimulation vs Sham Stimulation for Fecal Incontinence in Women: Neuromodulation for Accidental Bowel Leakage Randomized Clinical Trial. *Am J Gastroenterol.* 2022 Apr 1;117(4):654-667.
138. Zerbib F, Siproudhis L, Lehur PA, Germain C, Mion F, Leroi AM, et al. Randomized clinical trial of sacral nerve stimulation for refractory constipation. *Br J Surg.* 2017 Feb;104(3):205-213.
139. Zonić-Imamović M, Sinanović O, Imamović M, Muftić M, Janković S, Bazardžanović M. Effects of Transcutaneous and Percutaneous Tibial Nerve Stimulation in Bosnian Female Patients with an Idiopathic Overactive Urinary Bladder. *Acta Med Acad.* 2021 Aug;50(2):235-243.

---

"Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc. © 2022 Cigna.